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List of abbreviations 
ACN acetonitrile 
BAL British anti-Lewisite = dimercaprol 
BCA bicinchoninate anion 
BCS bathocuproin disulfonate 
CD circular dicroism (spectroscopy) 
COSY correlation spectroscopy (NMR) 
Cys cysteine 
DOSY diffusion-ordered spectroscopy (NMR) 
D-Pen D -penicillamine 
GSH glutathione 
His histidine 
HSAB hard-soft acid-base theory 
LHx different protonation states of the peptides 
LMCT ligand to metal charge transfer 
MD Menkes disease 
Met methionine 
MT metallothionein 
NOESY nuclear Overhauser effect spectroscopy (NMR) 
P general notation for the peptide, independent from the protonation state 
ROESY rotating-frame Overhauser spectroscopy (NMR) 
ROS reactive oxygen species 
TOCSY total correlation spectroscopy (NMR) 
UV-vis UV-visible (spectroscopy) 
WD Wilson’s disease 
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I. Introduction 
Copper is a transition metal found in group 11 of the periodic table, along with silver 
and gold (Figure 1). The name copper and symbol Cu are related to the Island of Cyprus, 
which was the main source of this metal in the Roman era. The phrase aes cyprium meaning 
the metal of Cyprus is believed to have evolved to cuprum and finally to copper.[1] 
 
Figure 1. The place of copper in the periodic table 
Copper was one of the first metals used and played an important role during history, 
because it can be found in elemental form, besides the various compounds, and it possesses 
useful physical properties, such as good ductility, malleability, strength, corrosion 
resistance, and high thermal and electrical conductivity, combined with an attractive 
appearance. From the primitive tools and weapons of prehistoric times, through the coinage 
and alloy formation to electrical wires and high-temperature superconductors in modern 
ages, there is a wide range of applications of copper and its compounds. They are also used 
as catalysts in both homogeneous and heterogeneous reactions, as fungicides, pesticides, 
wood preservatives, and as pigments for paints and glasses.[1] 
Copper is also an important element from the biological point of view. It is an 
essential micronutrient participating in several vital processes. Since copper can alternate 
between the Cu(I) and Cu(II) oxidation forms, it mainly acts as a cofactor of redox enzymes. 
Some examples of copper proteins are cytochrome c oxidase, a member of the cellular 
respiratory chain, Cu/Zn superoxide dismutase, which plays an antioxidative defense role, 
lysyl oxidase, which is responsible for the collagen cross-link formation, dopamine beta-
hydroxylase, that participates in catecholamine production and the two iron homeostatic 
proteins, hephaestin and ceruloplasmin.[2] 
Nevertheless, this electrochemical activity makes the excess free copper as well 
harmful for the cell. It can promote the formation of reactive oxygen species (ROS) in 
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Fenton-like reactions. It is well-known that ROS can damage all cellular compartments from 
lipid membrane to nucleic acids. Therefore, cellular copper concentration is under strict 
control involving a sophisticated system of proteins. 
Illnesses like Menkes or Wilson’s diseases (MD and WD, respectively) can disturb 
this sensitive balance leading to copper deficiency or overload. WD is treated by chelation 
therapy. However, the nowadays-used drugs induce several adverse side effects. Thus, there 
is a substantial need for the development of safer therapeutics. 
LITERATURE REVIEW 
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II. Literature review 
1. Overview of human copper homeostasis 
1.1. Copper sources 
Nutrition is the main source of copper for the human body. Foods that are rich in 
copper are the seeds, grains, nuts, beans, potato, tomato, shellfish and liver. Drinking water 
also contributes to the daily intake, but in significantly smaller quantity (1 μg/day) depending 
on the characteristics of water like pH, hardness or copper availability in the water supply 
network. The recommended amount of ingested copper per day is around 0.8 mg, but the 
exact value depends on the geographical location, the age or sex. 
In the proximity of industrial settlements such as mines or metal production plants, 
the copper level can be extremely high in the environment and it can be absorbed through 
the skin or by inhalation.[3] 
1.2. The route of copper in the body 
Dietary copper is absorbed by the enterocytes found in the wall of the small intestine. 
The enterocytes transfer copper to the portal circulation towards the destination of the liver. 
Liver is often called as the center of copper homeostasis, because copper is incorporated here 
into copper proteins and distributed to the other organs of the body. Excess copper is excreted 
through the bile in a form that cannot be reabsorbed and finally removed with the feces.[4] 
1.3. Coordination chemistry of copper in a living organism 
Copper has a d10s1 valence electron configuration and it is stable in Cu(I) and Cu(II) 
oxidation states. According to Pearson’s hard-soft acid-base (HSAB) theory Cu(I) is 
characterised as a soft Lewis-acid,[5] and consequently, it is often coordinated by 2, 3 or 4 
sulphur and nitrogen donors in linear, trigonal planar or tetrahedral geometry.[1] The 
borderline Lewis-acid Cu(II) can be coordinated by oxygen and nitrogen donors with 
coordination numbers 4–6 and in a square planar, (distorted) pentacoordinate or (distorted) 
octahedral geometries [1, 6]. In copper binding proteins these donor atoms are provided by 
the thiolate moieties of cysteines, the thioether groups of methionines, the carboxylate 
groups of glutamates and aspartates, the imidazole rings of histidines, and besides, the N- 
and O-atoms of the polypeptide backbone can also play a role in the coordination of Cu(II). 
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1.4. Cellular copper trafficking 
 
Figure 2. Cellular copper trafficking. Black arrows represent the route of copper; green arrows represent the 
movement of bigger units. Figure was made based on [4, 7]. 
Ctr1 
Copper enters cells by the transporter protein Ctr1 (Figure 2). Ctr1 has three 
transmembrane regions that position the N-terminal domain on the extracellular side and the 
C-terminal domain in the cytosol. The extracellular domain is rich in methionines arranged 
in MXXM or MXM motifs, while the C-terminal domain contains conserved cysteines and 
histidines (Figure 3).[8] 
 
Figure 3. Schematic representation of cellular copper uptake[8] 
A peptide modeling the first 14 amino acids of the extracellular N-terminal domain 
of Ctr1 (MDHSHHMGMSYMDS) is able to bind Cu(II) and Cu(I) with high affinity 
(logKCu(II) = 11.0 and logKCu(I) = 10.2) at pH = 7.4. Cu(II) is coordinated in square planar 
environment provided by the ATCUN motif formed by the amino nitrogen of the terminal 
nucleus
CcO
mitochondrion
ATP7A/B
Ctr1
GSH
MT
Cox17
Atox1 trans-Golgi 
networkCCS
SOD
Golgi vesicle
ATP7A/B
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Met, the amide nitrogens of the following two peptide bonds and the imidazole nitrogen of 
the His residue. Interestingly, Cu(II) can be reduced in this complex by ascorbic acid, which 
is not typical at all for the ATCUN motif. The reduction leads to the rearrangement of the 
coordination site. Cu(I) is bound in a distorted tetrahedral geometry by two imidazole 
nitrogens and the carbonyl oxygen of the bis-His motif and by a thioether sulfur of one of 
the methionines.[9, 10] 
Another peptide modelling the Met-rich motif of the N-terminal domain in the 
MXMXXM sequence was shown to coordinate Cu(I) in an all-methionine fashion. 
Dissociation constant of the 1:1 mononuclear complex was determined to be KD ~ 10
−6 at 
pH = 3.5-4.5. The peptide displayed high selectivity for Cu(I) since no Cu(II) species could 
be detected.[8] 
Based on UV-vis spectroscopic results, the cytosolic C-terminal domain of Ctr1 
binds four Cu(I) ions and structural investigation by X-ray absorption spectroscopy showed 
the formation of a cluster with a Cu4S6 core (Figure 4). ESI-MS experiments revealed that 
this Cu4 cluster was the only species formed, without the detection of any mono-, di- or tri-
metalated complexes. The KD ~ 10
−19 dissociation constant was determined by competition 
experiments.[11] 
 
Figure 4. Model of the Cu4S6 cluster. Brown spheres represent copper atoms and the yellow ones represent 
the sulfurs[11] 
Once copper is inside the cell, it binds to metallochaperones that incorporate it to 
copper dependent proteins, or to glutathione or metallothioneins for storage. 
Cox17 
Cox17 is one of the six chaperone proteins that transfer copper to the cytochrome c 
oxidase in the mitochondrion. It contains six conserved cysteines and exists in three 
oxidation forms, the fully reduced form with no disulfide bridges, the partially oxidized form 
with two disulfide bridges and the fully oxidized form with three disulfide bridges. 
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The fully reduced Cox17 binds four Cu(I) ions in a cooperative manner at neutral pH 
resulted in a tetranuclear cluster, where the metal ions are exclusively coordinated by the six 
cysteine thiolates. Decrease of pH leads to the dissociation of the Cu4Cox17 complex starting 
at pH = 4.8. Other forms with one or five bound Cu(I) are also detectable, but the 
intermediate Cu2Cox17 and Cu3Cox17 are absent. Fully reduced Cox17 also can bind a 
maximum of two Zn(II) ions, but in a non-cooperative manner. This is explained by the 
different coordination preferences of Cu(I) and Zn(II). Although Ag(I) and Cu(I) have 
similar coordination properties, Cox17 cannot be reconstituted with Ag(I), possibly because 
of its larger size. 
Partially oxidized Cox17 can bind one Cu(I) or Zn(II) at neutral pH. This Cu(I) 
complex decomposes at higher pH than the Cu4S6 cluster of the fully reduced form, 
indicating the participation of other amino acid residues, like histidine or methionine, in the 
coordination. No metal complexes of the fully oxidized protein have been detected.[12, 13] 
Atox1 
Atox1, also known as HAH1, is a human copper chaperone playing a similar role to 
Atx1 in yeast.[14, 15] These proteins contain a MxCxxC metal binding motif and transports 
copper to their target copper ATPases, namely ATP7A and ATP7B in humans. 
The stoichiometry of the Cu(I)-Atox1 complex was determined by the addition of the 
protein to the solution of the [Cu(BCA)2]
3− complex (BCA = bicinchoninate anion). 
Spectroscopic results showed that protein bound one equivalent of Cu(I). A similar 
experiment with [Cu(BCS)2]
3− complex (BCS = bathocuproin disulfonate) led to the 
determination of the KD = 3.9 × 10−18 dissociation constant at pH = 7.0.[16] 
The interaction of Atox1 with Hg(II) was also studied by means of 199Hg NMR, 
119mHg PAC, UV-vis spectroscopy and gel-filtration. It was shown that at pH = 7.5 Hg(II) 
was bound to the monomeric protein via the two Cys residues in a linear geometry. At pH = 
9.4 Hg(II) promoted the dimerization of the protein leading to the formation of a mixture of 
T-shaped HgS3 and a distorted HgS4 species.[17] 
ATP7A and ATP7B copper-transporter  
ATP7A and ATP7B are copper transporter P-type ATPases. These transmembrane 
proteins use the energy obtained from the hydrolysis of ATP for the transport of copper 
across the cell membrane. They are localized in the membrane of the trans-Golgi network. 
Their main function is to distribute copper to the main enzymes such as ceruloplasmin by 
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transferring copper from the cytosol to the Golgi, and to help maintaining the optimal 
intracellular copper concentration. In case of increased copper concentration, vesicles are 
formed from at Golgi membrane and migrate to the cell membrane to expel Cu from the cell. 
ATP7A is expressed in all types of cells except liver and ATP7B is expressed in the liver 
and the brain. ATP7A present in the enterocytes of the small intestine is responsible for the 
regulation of copper absorption by trafficking copper from the intestine to the blood. ATP7B 
participates in the excretion of excess copper to the bile.[4] 
ATP7A and ATP7B display 54% identity in their amino acid sequence. They both 
contain six MxCxxC metal binding motifs at the cytosolic N-terminal domain. The overall 
structure of these domains are similar, each of them bind one Cu(I) ion by the two cysteine 
residues in a solvent exposed loop.[18] The increase of Cu(I) concentration does not affect 
Cu(I) binding. The linear geometry, ideal for the two-coordinate binding mode is distorted 
with a S-Cu-S bond angle between 120° and 180°.[19] A model peptide, involving the 5th 
and 6th metal binding domains, was shown to bind two Cu(I) ions separately by a similar 
experiment like in the case of Atox1. Nevertheless, only one dissociation constant, KD = 4.0 
× 10−18could be determined at pH = 7.0, indicating a similar affinity of the two metal binding 
domains for Cu(I).[20] 
Glutathione 
Glutathione (GSH) is a ubiquitous tripeptide (Figure 5). It plays an essential role in 
cellular redox regulation, detoxification and signaling functions. Besides, with its thiol 
groups it often acts as a ligand for soft transition metal ions. It was shown that GSH forms a 
Cu4S6 type cluster with Cu(I) under physiological concentration. The stability of the cluster 
permits only femtomolar concentration of free Cu(I) in the cell. In other words, the existence 
of an intracellular Cu(I) pool that are buffered to the upper femtomolar or picomolar 
concentration range is precluded by normal physiological level of GSH.[21] 
 
Figure 5. Schematic structure of glutathion 
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Metallothioneins 
In 1957 Margoshes and Vallee identified a small, cysteine rich Cd(II) binding protein 
in horse kidney.[22] Later it turned out, that this was the first member of the superfamily of 
metallothioneins (MT). MTs are found from bacteria to humans in several isoforms showing 
diversity in the amino acid sequences and therefore in metal binding properties, three 
dimensional structures and functions. Characterizing features are the followings: 
 low molecular mass combined with high cysteine content arranged in the typical CxC, 
CxxC or CCxxCC motifs. Figure 6 shows the position of cysteines in the sequence of a 
rabbit liver MT as an example. 
 binding to Zn(II) and/or Cu(I) under physiological conditions, but also displaying high 
affinity for non-essential d10 metal ions. 
 high thermodynamic stability combined with kinetic lability. 
 the three dimensional structure is dictated by the bound metal ions, while the ApoMTs 
lack any secondary structure. 
 formation of characteristic metal clusters with typical spectroscopic features. 
 the absence or scarcity of aromatic amino acids.[23, 24] 
 
Figure 6. The position of cysteines in the sequence of a metallothionein from rabbit liver adapted from the 
figure of Stillman[25] 
Different MT isoforms are expressed in different tissues under different conditions 
and therefore it is hard to define their function. As Blindauer claims the “enigmatic unified 
function of MTs does not exist”.[23] MTs participate in the regulation of the essential Zn(II) 
and Cu(I) ions and in the detoxification of the toxic Hg(II) and Cd(II). They can be also 
related to anti-inflammatory, anti-apoptotic, antioxidant, proliferative and angiogenic 
processes. 
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The structures of the divalent metal ions complexes of metallothioneins are well-
characterized. Generally, seven Zn(II) or Cd(II) ions are bound per metallothionein protein 
in an M4(SCys)11 cluster in the α domain and in an M3(SCys)9 cluster in the β domain (Figure 
7). The metal ions display a tetrahedral coordination in both clusters. The α domain cluster 
can be described as two fused six-membered ring sharing two M(II)-SCys bonds. Thus, there 
are five bridging and six terminal cysteine thiolates. In the M3(SCys)9 cluster three metal ion 
and three bridging thiolates form a six-membered ring in a distorted chair conformation, 
while the other six thiolates act as terminal ligands.[24] 
 
Figure 7. 3D structure of the human Cd7-MT2 showing the β domain enclosing the Cd3(SCys)9 cluster (A) and 
the α domain with the Cd4(SCys)11 cluster (B).[24] 
The formation of several Cu(I)-thiolate complexes of metallothioneins was 
evidenced by spectroscopic experiments. Cu(I) ions are coordinated digonally or trigonally. 
The thiolates act as bridging or terminal ligands. A metallothionein, isolated from rat liver 
was shown to bind 12 equivalents of Cu(I) per MT, which were distributed in two M6 clusters 
of the α and β domain.[26] Yeast metallothionein formed a Cu8(SCys)12 cluster in all-or-
nothing manner.[27] Cu8-MT and Cu12-MT species were evidenced in MT-1 isolated from 
rabbit liver depending on the Cu(I):MT concentration ratio. These two complexes are built 
up by two Cu4(SCys)6-7- and Cu6(SCys)10 clusters, respectively.[28] Neuronal growth 
inhibitory factor (GIF) is a brain specific metallothionein. It forms a Cu4Zn3-GIF species. 
The study of the N-terminal (β) domain showed the formation of two well-defined Cu(I) 
clusters involving nine cysteine thiolates and 4 or 6 Cu(I) ions.[29] The Roman snail 
metallothionein is saturated by 12 Cu(I) ions.[30] As an explanation for such a diverse Cu-
cluster formation, the possibility of different types of bound Cu(I) was proposed based on 
the results of a competition study with Cu(I) chelators. This experiment indicated that two 
of the eight Cu(I) ions of the yeast MT cluster were easily removable.[31] Later, it was 
shown that the formation and the structure of the Cu(I) complex of rabbit liver MT were 
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temperature dependent. At low temperature, the MT is relatively constrained and only the 
formation of a Cu12-MT species is favored. In contrast, at higher temperature it becomes 
flexible enough to form a Cu9Zn2-MT complex.[32] 
Although Cu(I) metallothioneins are widely studied, only the crystal structure of the 
truncated yeast Cup1 is available (Figure 8),[33] because of the relatively high flexibility of 
the protein backbone. The largest Cu(I)-thiolate cluster in biology was identified in Cup1 
with the participation of six trigonally and two digonally coordinated Cu(I) bound by ten 
cysteine residues. The two digonally coordinated Cu(I) are located at the opposite site of the 
cluster which perhaps have a role in copper transfer to other proteins. 
 
Figure 8. 3D structure of the Cu complex of a truncated form of Cup1 from S. cerevisiae, showing the 
Cu8(SCys)10 cluster[24, 33] 
The interaction between metallothioneins and metal ions, including Cu(I) is often 
studied by complementary spectroscopic methods. CD spectroscopy can be efficiently used 
because MTs do not contain aromatic amino acids or disulfide bonds, which have CD 
contribution in the wavelength range of thiolate-metal ion charge transfer (LMCT) 
transitions (230-400 nm). Besides, MTs are large enough to have a secondary structure in 
the presence of metal ions, but they are small enough to avoid possible compensation of the 
CD contributions of chromophores. The thiolate-Cu(I) LMCT has characteristic absorption 
in the UV region around 260 nm. However, it depends only on the net increase of Cu-S 
bonds and thus it is a good indicator for the formation of new Cu-S bonds.[34] The UV 
absorption spectrum of a Cu-MT system can be divided into the two distinct low- and high-
energy regions. This latter one belongs to the electric dipole allowed thiolate to Cu(I) charge 
transfer (LMCT) occurring around 260 nm. The lower energy absorption is attributed to 
formally spin-forbidden 3d → 4s metal cluster centered transitions.[28] 
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2. Copper related disorders 
2.1. Copper toxicity 
Substances can be characterized as essential or toxic depending on the biological 
response that they induce. Essential elements have an optimal concentration range for a 
normal functioning, which varies from element to element. Concentration outside this 
optimal range causes health problems. The dashed line in Figure 9 shows that toxic 
substances have only negative effects, however it can also be seen that the body can cope 
with a small amount of the given element before toxic effects become apparent.[35] 
 
Figure 9. Dependence of biological response on concentration of an essential nutrient (solid line) and of a 
toxic substance (dashed line) in tissues.[35] 
Copper toxicity is originated from unspecific interactions with proteins that disturb 
or inactivate the protein functioning. Toxicity may result from: (I) binding to sulfhydryl 
groups in proteins, thereby inhibiting enzyme activity or protein function; (II) initiating the 
deficiency of other essential ions; (III) impaired cell transport processes; and (IV) oxidative 
damage.[6] Among these, the main problem is attributed to the production of strong 
oxidizing agents. For a long time, it was supposed that these oxidants were ROS produced 
mainly in Fenton like reactions [36, 37]: 
Cu+ + H2O2 ⇌ Cu2+ + OH• + OH− 
Cu2+ + H2O2 ⇌ Cu+ + HOO• + H+ 
The reactions of Cu(I) and Cu(II) with H2O2 in the presence of O2 at pH = 8.0 have 
been studied.[38] The results showed that, on one hand, Cu(II) reacted with H2O2 in the 
classical free radical mechanism producing Cu(I) and O2
•−. The formed Cu(I) was able to 
react with excess H2O2 to produce OH
•. On the other hand, a well-known hydroxyl radical 
indicator did not show the formation of OH• in reaction between Cu(I) and H2O2. However, 
the involvement of an intermediate species of copper in a higher oxidation state (Cu(III)) 
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Excess
Essential
Toxic
Possible death
Concentration
R
e
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o
n
se
+
−
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was assumed, but its reaction with the substrates was several orders of magnitude slower 
than OH•. Formation of OH• from the dissociation of Cu(III) was determined to be extremely 
slow at pH 8.0. This result showed that OH• was not an important oxidant in this system. 
2.2. Alzheimer’s disease 
Alzheimer’s disease (AD) is the most common neurodegenerative disorder. It is 
associated with the misfolding of the amyloid-β peptide forming fibrils and plaques in brain 
tissue. In the development of AD, a key role is attributed to ions of metals such as copper, 
zinc or iron, which can affect the aggregation and redox properties of the amyloid-β peptide. 
Metal binding sites of amyloid-β are found between the 1-16 amino acids of the sequence. 
The coordination of Cu(II), Cu(I) and Zn(II) is presented in Figure 10. Two different binding 
modes of Cu(II) are known, component I is favored at lower pH, while component II is 
present at higher pH. Both are characterized by a distorted square planar geometry and by 
the participation of amino nitrogen of Asp1 at the N-terminus. In component I, Cu(II) is also 
bound to the carbonyl oxygen of the Asp1-Ala2 peptide bond and two histidine nitrogen 
atoms of the His6 residue and one of His13 and His14 which are in equilibrium. In 
component II, the deprotonated amide nitrogen of the Asp1-Ala2 peptide bond, the carbonyl 
oxygen of the Ala2-Glu3 bond and a histidine nitrogen bind to the Cu(II) ion. Cu(I) is 
coordinated in a linear fashion by two of the imidazole nitrogen atoms from the dynamic 
equilibrium of His6, His13 and His14 with a preference for the His13-His14 couple. Zn(II) 
is tetrahedrally coordinated by two histidine residues (His6 and His13 or His14) and two 
carboxylate residues from Asp1, Glu3 or Asp7, where the Asp1 is favored. Stability 
constants were determined in the range of 109-1010 for Cu(II), 107-1010 for Cu(I) and 105 for 
Zn(II).[39] 
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Figure 10. The main coordination modes of amyloid-β peptide with Cu(II), Cu(I) and Zn(II)[39] 
2.3. Menkes disease 
Menkes disease (MD) is due to the mutations of the ATP7A gene found on the X 
chromosome. This induces dysfunctions of the ATP7A copper transporter, and copper 
cannot be absorbed and hence patients suffer from copper deficiency. Clinical symptoms 
usually appear in boys at the age of 2-3 months with a subsequent loss of previously obtained 
developmental milestones.[40] Children die in their early childhood. All patients gain very 
little weight following birth. The clinical symptoms of MD can be traced back to the 
deficiency of developmentally important copper enzymes. The impairment of lysyl oxidase, 
a protein needed for crosslink formation in connective tissues, causes the weakening of 
connective tissues that leads to arterial ruptures or skin laxity. Low levels of cytochrome c 
oxidase cause temperature instability and the absence of tyrosinase explains the hair 
depigmentation.[41] MD is also characterized by mental retardation and neurodegeneration. 
The current treatment is copper supplementation, which can be highly effective 
depending on the type of the ATP7A mutation and the timing of treatment.[40, 42] Far 
perspective is the adeno- associated virus-mediated gene therapy.[40, 43] 
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2.4. Wilson’s disease 
Wilson’s disease (WD) is induced by the monogenic, autosomal recessive mutation 
of ATP7B presented in a high variety of point or splice junction mutations (more than 500 
are identified).[40] The mutations lead to the loss of ATP7B function, and hereby to the 
accumulation of copper in the liver, and later, in the central nervous system. There are three 
phases in the progression of WD. In the first phase copper starts to accumulate in the 
cytoplasm of hepatocytes. The increased copper concentration induces the expression of 
high amounts of metallothioneins in the second phase and the formation of copper storages 
in the liver, which cause cell death and the release of copper to the blood stream. In the third 
phase, copper accumulates in other organs, such as brain, kidney and eyes.[41] WD is 
characterized by three groups of symptoms: (I) hepatic, like jaundice, acute hepatitis, liver 
failure, cirrhosis1; (II) neurological, like movement disorders or tremor; (III) psychiatric e.g. 
personality changes, paranoia, depression and schizophrenia[44]. Symptoms usually appear 
in the age between 5 and 35 years, but there were patients who became symptomatic when 
they were older than 70 years.[40] Generally, children are diagnosed with WD by the 
manifestation of liver problems, while adults by neurological symptoms. It is assumed that 
patients with neurological disorders also have asymptomatic liver disease. WD is 
characterized by the Kayser-Fleisher rings of copper deposition in the eyes and low serum 
ceruloplasmin concentration.[44] Wilson’s disease is treated by chelation therapy. In case of 
fulminant liver failure, transplantation is required. Without treatment, WD is lethal. 
2.5. Further disorders associated with copper overload 
Copper accumulation is associated with other liver damages than Wilson’s disease. 
Indian childhood cirrhosis, Endemic Tyrolean infantile cirrhosis and Idiopathic copper 
toxicosis were found to be identical,[45] but they were present in different places, in India 
and different regions of Austria. It was caused by the high copper exposure originated from 
the consumption of milk stored and heated in copper or copper-alloy utensils. After the 
instruction of the population to avoid the use of such containers in 1974, no new cases were 
reported. The collected data suggest that the development of cirrhosis is a result of the 
synergy of excess copper intake and non-Wilsonian genetic susceptibility for impaired 
copper metabolism.[3, 46] 
                                                 
1 Liver damage that is characterized by the replacement of normal liver tissue by scar tissue. 
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3. Strategies in the treatment of Wilson’s disease 
3.1. Historical and current treatments 
Chelation therapy is widely used for the treatment of toxic metal poisoning and in 
diseases related to metal overload. In general, chelation therapy refers to the administration 
of a chemical agent to remove heavy metal ions from the body (Figure 11). 
 
Figure 11. Schematic representation of the mode of action of a chelator[47] 
This chemical agent is a so-called chelator, originated from the Greek word “chele” 
for claw, because as the molecule binds to the metal ion, it resembles to how the lobster 
catches its prey. A chelator possesses more than one donor group and therefore it forms a 
ring around the metal ion during the coordination. This provides higher complex stability 
than monodentate ligands of the same donor atom and it is called chelate effect. Chemical 
properties like charge, solubility, lipophilicity, redox potential, geometry and pH 
dependence, kinetics and thermodynamics of the exchange of the ligand or the metal ion can 
all influence the behavior of a chelator and its metal complex in biological conditions.[47] 
Drugs used for the treatment of Wilson’s disease are presented in Figure 12. 
Dimercaprol (British anti-Lewisite, BAL) and its derivatives, dimercapto-propanesulfonic 
acid (DMPS) and dimercapto-succinic acid (DMSA) are general chelating agents that were 
first applied against copper overload in Wilson’s disease. Later, they were replaced by D-
penicillamine (D-Pen) and triethylenetetramine (trien). Tetrathiomolibdate (TTM) is 
currently under investigation. Besides chelation, Wilson’s disease is treated by zinc therapy, 
which limits the copper absorption in the intestine. 
24 
 
Figure 12. Schematic structure of the drugs used for the treatment of Wilson’s disease 
An ideal treatment for Wilson’s disease should consist of two phases. First, it has to 
be started with an aggressive de-coppering phase to decrease the amount of copper 
accumulated in the body. This should be followed by a maintenance therapy of reduced doses 
to control a normal copper homeostasis. Refinement and adjustment of this second phase 
could also be necessary to avoid copper deficiency caused by overtreatment.[40] 
BAL 
Dimercaprol, also called as British anti-Lewisite or BAL, was developed against 
arsenic poisoning caused by the warfare gas Lewisite in the Second World War. Later it was 
also used for the intoxication of mercury, gold, lead, antimony, bismuth, copper and nickel. 
After the identification of the relationship between the Wilson’s disease and copper 
overload, BAL was the first drug proposed for the treatment. BAL is an oily, highly 
hydrophobic substance and therefore it has to be administered by the painful intramuscular 
injection. It was usually mixed with the highly allergenic peanut oil. As a result of the 
treatment, patients showed remarkable improvements and increased urinal copper excretion. 
However, BAL induces many side effects, such as the increase of blood pressure, nausea 
and vomiting, headache, burning feeling of the lips, mouth or throat and painful irritation at 
the injection site.[48] The orally administrable BAL derivatives DMSA and DMPS were 
used only in China for the treatment of Wilson’s disease.[49] 
Interestingly, although BAL has been used for several decades, its interaction with 
copper ions was just recently described.[50] The reaction between copper ions and thiols 
usually occurs in the following way: 
2Cu(II) + 2RSH ⇌ 2Cu(I) + RSSR + 2H+ 
Cu(I) + RSH ⇌ Cu-SR + H+ 
Reaction between BAL and CuSO4 or CuCl2 results in the formation of a dark blue 
to grey, solvated suspensions of a mixture of species with stoichiometries of 2 Cu(I)/oxidized 
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dimeric BAL and Cu(II)/BAL 1:1. Because of the empty coordination site of Cu(I), 
polynuclear species were suspected, but their nature could not be revealed. Reaction of BAL 
with CuCl in methanol gave the Cu(I)2-BAL salt as a dark green solid, insoluble in organic 
solvents, displaying the same IR spectrum than the product of the reaction with CuCl2. 
Solubilization of these solids failed indicating that the urinary extraction of copper by BAL 
proceeded through another mechanism than the formation of a simple binary complex. 
D-Penicillamine 
D-Penicillamine (D-Pen) is a metabolite of penicillin. It was first used for WD 
treatment in 1955 according to the proposal of Walshe.[51] Since then, it is still the first drug 
of choice. The great advantage of D-Pen compared to BAL is that it can be orally 
administered, making it more convenient and more effective. However, D-Pen has also side 
effects, like fever, rash or renal toxicity.[3] It causes pyridoxine (vitamin B6) deficiency and 
interference in collagen and elastin formation leading to skin lesions and immunological 
problems.[52] Furthermore, worsening of neurological problems was registered in a 
significant number of patients after the treatment with D-Pen.[2] 
D-Pen is characterized by three protonation constants belonging to the thiol (logK = 
10.8), the NH3
+ (logK = 8.1) and the carboxyl groups (logK = 2.2). The dominant species at 
physiological pH is the zwitterionic form.[53] D-Pen can bind Cu(II) as a bidentate ligand 
via the thiol and amino groups and a redox reaction occurs between the metal ion and thiol 
group. The reduction of the metal ion induces changes in the preference of the coordination 
geometries. If D-Pen coordinates to a Cu(II) bound to a protein and the protein is not flexible 
enough to follow this change, the copper-protein interaction becomes weak and the metal 
ion is more readily removable.[54] Based on potentiometric and spectroscopic results, the 
formation of a stable and red-violet colored, mixed-valance species was proposed (Figure 
13).[3, 55] This species was suspected to have a key-role in urinary copper extraction by D-
Pen. 
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Figure 13. The proposed mixed-valance copper–D-Pen complex[3, 55] 
When D-Pen was added to the copper-albumin complex, the formation of a yellow 
brown species was observed. However, after a few minutes the solution became red-violet, 
indicating that the ternary complex transformed into the mixed-valance complex (Figure 
13).[3, 56] 
The interaction of the disulfide derivative of D-Pen with Cu(II) was also studied.[3, 
57] The monomeric CuLH and dimeric Cu2L2 complexes were formed with stability 
constants of logβCuLH = 15.8 and logβCu
2
L
2
 = 27.9 determined by pH potentiometric 
measurements. Cu2L2 dominated over pH = 3.5. Cu(II) ions were bound via the oxygen and 
nitrogen atoms of the ligand, but the sulfurs of the disulfide bridge did not participate in the 
metal ion coordination (Figure 14). 
 
Figure 14. Schematic structure of the Cu2L2 complex of the disulfide D-Pen[57] 
It was also stated that D-Pen could participate in copper detoxification by inducing 
the synthesis of metallothioneins in the liver.[49] 
Triethylenetetramine 
Triethylenetetramine, also known as trientine or trien also acts by increasing urinary 
copper extraction. It was first used in patients who intolerated D-Pen.[58] This drug has 
fewer side effects compared to D-Pen.[52, 59] In cases when the treatment with D-Pen had 
to be suspended, it could be efficiently continued with trien.[60] 
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Trien contains four amino nitrogen donor groups allowing the binding of copper in 
Cu(II) form. The interaction between trien and its metabolites (mono- and diacetylated) and 
Cu(II) and Zn(II) was studied by potentiometric and photometric studies.[61] Cu(II) 
complex formation resulted in the appearance of two bands on the UV-vis spectra, one 
centered at 250 nm and one at 580 nm with lower intensity. Data analysis revealed the 
formation of a CuLH complex at low pH, which completely transformed into the CuL 
complex at pH ~ 3.0. Cu(II) was coordinated by the four nitrogens of trien in a planar ring. 
Zn(II) complexes also formed but with significantly lower stability. ZnL formation occurred 
at a ~ 2.5-unit higher pH relative to the formation of the CuL complex. The acetylated 
metabolites formed the same type of metal complexes, but they displayed lower stabilities. 
Sarkar and coworkers analyzed ternary systems of Cu(II), human serum albumin and 
trien or D-Pen. They found that trien efficiently removed the metal ion from the Cu(II)-
albumin complex at neutral pH forming small membrane-diffusible, low molecular weight 
complexes. In contrast D-Pen was unable for such a Cu(II) removal. These results lead to the 
conclusion that the two kinds of chelators targeted different copper pools. Trien reduced the 
Cu(II) concentration in the blood stream, while D-Pen mobilized copper from the tissues.[62] 
To increase the efficiency of trien, it was encapsulated into surface modified 
liposomes.[63] Such a colloidal carrier can penetrate the blood-brain barrier and the copper 
overload in the central nervous system can be treated by the released trien. 
Improvement after the treatment of either D-Pen or trien was significant in patients 
with hepatic problems, but the therapy was less effective in the case of neurological 
symptoms. Both drugs induced the worsening of neurological problems in 20% of the cases. 
This deterioration was attributed to the initial large dose of the chelating agent and led to the 
hypothesis of the presence of two different kind of copper pools, the high-affinity bound 
copper (bound to ceruloplasmin) and free copper (not bound to ceruloplasmin). A plausible 
mechanism of the paradoxical neurological deterioration could be the overmobilisation of 
copper by chelation therapy, leading to an increased free copper pool with toxic effects.[40] 
Tetrathiomolybdate 
TTM has a high affinity for both Cu(I) and Cu(II) forming polymetallic clusters.[64] 
Solution equilibrium speciation and stability data, however, have not been reported yet, 
because of the complexity of the system. For instance, Mo, Cu and S can be present in 
different oxidation states, Cu and Mo can precipitate as sulfide and the hydrolysis of MoS4
2− 
28 
and Cu(II) can occur.[3] Nevertheless, X-ray absorption spectroscopy showed the formation 
of different species of Cu/ MoS4
2− stoichiometry ranging from 1:1 to 4:1 (Figure 15). 
 
Figure 15. The formation of different Cu-TTM complexes with increasing Cu concentration.[3, 65] 
TTM has two ways of action. When ingested with food, TTM forms complexes with 
dietary copper and thereby prevents the absorption of metal ion. When TTM is added 
between meals, it can be absorbed and forms ternary complexes with copper and proteins 
like albumin or metallothioneins in the blood stream. In this way copper becomes 
unavailable for the body and is excreted through the urine or the bile.[3, 52] 
Originally, TTM was used to treat animals with copper toxicosis and later it was 
applied for patients who were intolerant for D-Pen. The application of TTM does not cause 
the worsening of neurological problems and it has fewer side-effects. These side-effects are 
probably related to the extensive copper removal. Nevertheless, clinical data about TTM is 
limited and the drug is not commercially available.[3] 
The effectiveness of BAL, D-Pen, trien and TTM was compared according to their 
demetallation ability of two Cu(I)-binding proteins, the copper chaperone Cox17 and a 
metallothionein.[66] All of the drugs were able to remove Cu(I) from CuCox17, but in 
different concentrations. D-Pen was necessary to be applied in the highest amount followed 
by trien and BAL, while TTM was found to be 1000 times more efficient than the others. 
Demetallation of Cu10MT was more complicated. Cu(I) withdrawal started only after the 
binding of four TTM molecules, that probably opened the cluster and Cu(I) could dissociate 
from the protein. TTM was still the most efficient since 1000x higher concentration of the 
other drugs had to be applied to reach the same result. 
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Zinc therapy 
Administration of zinc-acetate to WD patients limits the intestinal copper absorption. 
Zn(II) stimulates the synthesis of metallothioneins in the intestinal epithelial cells. MTs bind 
dietary copper therefore prevent further copper accumulation.[40] MT-bound copper is 
excreted through peeling of enterocytes within some days via the feces.[2, 67] Since zinc 
and copper are uptaken by the same carriers of the enterocytes, saturation of these carriers 
with Zn(II) can block the absorption of Cu(II).[68] Zinc therapy has significantly fewer side 
effects than chelating agents. Nevertheless, the proposed daily dose of zinc (600 mg)[69] is 
notably higher than the normal dietary uptake, which can induce adverse gastrointestinal 
effects. Zinc is recommended as a maintenance therapy after the initial chelation therapy and 
for the treatment of asymptomatic or presymptomatic family members of Wilson’s disease 
patients.[64] 
3.2. New perspectives 
Targeting intracellular Cu(I) of hepatocytes 
In modern drug research, it is a rule of thumb to develop specific treatments for the 
different diseases to reduce the side-effects. Two basic concepts for the achievement of this 
goal are the so-called drug targeting and the use of pro-drugs. When a drug is targeted to a 
specific organ, it is functionalized in a way that it can be absorbed only by cells of this organ. 
A pro-drug is an inert compound where the functions responsible for the curative effect are 
inactivated.[70] It becomes active only at the required site through metabolism.[71] In 
chelation therapy it is also important that the chelating agent should be highly selective for 
the metal ion to be removed in order to avoid disturbance in the homeostasis of other 
essential metal ions, like Zn(II) or Ca(II). 
In the case of Wilson’s disease these concepts can be realized by means of targeting 
Cu(I) in liver cells because of the following reasons.[4, 72] Copper taken up by the cells is 
in the Cu(I) oxidation state and the millimolar intracellular concentration of gluthation 
(GSH) [73] makes its oxidation to Cu(II) very unlikely. 
2 Cu2+ + 2 GSH ⇌ 2 Cu+ + GSSG + 2 H+ 
Accordingly, an efficient chelator has to be selective for this Cu(I) form. The HSAB 
theory [5] and the metal binding sites of proteins may provide some hints on how to choose 
an optimal set of donor groups for Cu(I). The thiol functions of cysteines, as soft bases, often 
participate in the ligation of the Cu(I) ion, also possessing a soft character. Further advantage 
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of cysteines is the fact that they easily form disulfide bridges, which are inactive in metal 
ion chelation. These disulfide bridges can be broken in the reducing intracellular medium 
and thus the active chelator is released. In this way, cysteines also fulfill the pro-drug 
concept. 
Finally, since liver is the center of copper homeostasis and therefore mostly affected 
in Wilson’s disease, an efficient drug targeting strategy could be if the new product was 
targeted to this organ. 
The Delangle group aims to find an efficient Cu(I) chelator and then functionalize 
this ligand to target the liver cells. Their first tested ligands were inspired by the metal 
binding sequence of the Atx1 [14, 15] copper chaperone protein.[74] Both the linear Ac-
MTCSGCSRPG-NH2 and the cyclic c(MTCSGCSRPG) peptides displayed an outstanding 
selectivity towards Cu(I) over Zn(II), Cd(II) and Pb(II). The peptides formed the 
mononuclear CuL complex under ligand excess conditions with logβ = 16-17 apparent 
stabilities at pH = 7, which is in the same range as the native Atx1 protein (logβ = 18 at pH 
= 7.4).[11] However, at higher Cu(I) concentration, the formation of polynuclear species 
was observed. These experiments showed that the insertion of the xPGx motif and the 
cyclization of the peptide backbone did not disturb the complex formation, moreover, the 
complexes of the cyclic peptide displayed systematically higher stabilities with all the metal 
ions. This effect was attributed to the preorganization of the binding loop positioning the 
two cysteine side chains on the same side of the macrocyclic peptide. 
The other direction in Cu(I) chelation research was based on the use of tripodal 
pseudopetide ligands. In this kind of ligands three derivatives of cysteine [75, 76], D-
penicillamine [77], methionine or methyl cysteine [78] were anchored on a nitrilotriacetic 
acid (NTA) scaffold to mimic the high S-density of metallothioneins (Figure 16). A great 
advantage of this scaffold is that all the metal binding arms were oriented to the same 
direction forming a metal binding cavity. 
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Figure 16. Schematic structures of the tripodal ligands [76-78] 
Three cysteine-based ligands were investigated. These molecules differed in the 
nature of the carbonyl function and this difference was proved to have a great effect on the 
complexation properties. 
The ligand bearing three carboxylate functions only formed non-defined (Cu2L)x 
polymetallic Cu(I) species of low stability. This destabilizing effect was probably due to the 
large electrostatic repulsion between the negative charges of the three carboxylate groups at 
physiological pH, which were brought closer to each other in the complex. The mononuclear 
Cu(I) complexes of the two other ligands with ester and amide groups were the first 
described water soluble CuS3 species. The Cu(I) ion was bound in symmetrical trigonal 
planar geometry in these complexes suggesting that the cavity of these NTA based ligands 
was perfectly adapted to the coordination of Cu(I).[79] Temperature dependent NMR 
measurements proved that the cavity was stabilized by a network of hydrogen bonds in the 
upper cavity involving the NH of one arm and the C=O of the next arm.[76] 
In excess of Cu(I), the mononuclear CuL complex transformed into the Cu6L3 cluster, 
as presented in Figure 17. The amide derivative showed the greatest tendency to form the 
cluster from the mononuclear complex. 
 
Figure 17. Structure of the Cu(I) complexes of the tripodal ligands [75] 
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The stability constants logβ11pH 7.4 ~ 19 obtained for the mononuclear complexes are 
in the range of those reported for metallothioneins.[80] The molecules displayed an 8-9 
orders of magnitude larger affinity towards Cu(I) with respect to Zn(II). 
D-Pen, as the most frequently used drug for Wilson’s disease, was also an interesting 
candidate to be anchored on the NTA scaffold. The two D-Pen based ligands with amide and 
ester groups on the carbonyl functions showed significantly different complexation behavior 
with Cu(I), probably due to the different size of these groups. The ligand bearing the bulkier 
ester group formed exclusively the well-defined Cu4L2 cluster with the Cu4S6 core, while the 
other compound formed the mononuclear CuL complex in the presence of ligand excess and 
the same type of Cu4L2 cluster under Cu(I) excess conditions. Trigonal planar coordination 
around Cu(I) was proved with the participation only of the sulfur donors and Cu-S distances 
characteristic for the CuS3 geometry. The ligands bound Cu(I) tightly with affinities of 
logβ = 16-17, which were lower than those determined for the cysteine derivatives, but 
significantly higher than the affinity reported for the D-Pen alone.[81] The studied ligands 
also displayed remarkable selectivity in favor of Cu(I) relative to Zn(II). 
The thioether derivatives were inspired by the methionine rich motifs of the Ctr1 
protein. The ligands exclusively formed mononuclear complexes with Cu(I) even in the 
presence of excess metal ion. The obtained logβ = 10-11 stabilities were significantly lower 
than those of the thiolate ligands, but higher than the logβ = 5-6 values reported for linear 
peptides mimicking isolated methionine-only binding sites found in Ctr1 sequences.[8, 82] 
As a second step in the research, the two most promising ligands, the peptides and 
the cysteine based tripodal pseudopeptides were functionalized for drug targeting as 
presented in Figure 18. Since the drug should be selectively absorbed in hepatic cells, the 
asialoglycoprotein receptor (ASGP-R) was chosen as a target.[83-85] The ASGP-R is 
predominantly expressed on the surface of hepatocytes [86, 87] and recognizes terminal 
galactose (Gal) and N-acetylgalactosamine (GalNAc) with higher affinity.[88] The ASPG-
R mediated targeted drug strategy was successfully applied for the specific delivery of 
antiviral [89, 90] and anticancer drugs [91-93], and gene therapeutic agents [94-98] to 
hepatocytes in vivo. 
The glycocyclodecapeptide ligand was designed by the regioselectively addressable 
functionalized template (RAFT) concept [99] to distinguish the Cu(I) chelating unit with two 
cysteine side chains hidden in a disulfide bridge and the ASPG-R recognition unit with a 
cluster of four GalNAc carbohydrates on two independent faces.[100] In the sulfur tripod 
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glycoconjugate, the thiol functions were masked by tethering one GalNAc with an ethylene 
glycol spacer to each arms through disulfide bonds (Figure 18).[101]  
 
Figure 18. Design and mechanism of action of the two glycoconjugates 
The efficiency of the targeting units was proved by the uptake of a fluorescent 
analogue of both ligands by various hepatic cell lines.[100, 101] The peptide based product 
was better internalized than the triopdal one.[102] The disulfide bridges hid the chelating 
binding sites and, as expected the ligands did not show Cu(I) chelating properties. When the 
disulfide bridges were reduced in the intracellular medium, the ligands lowered the Cu(I) 
concentration which was monitored by the trafficking of the copper ATPase ATP7B.[100, 
101] The intracellular Cu(I) chelating efficiency of the two glycoconjugates was similar, 
although the affinity of the released chelators for Cu(I) differed by three orders of magnitude 
in favor of the tripod derivative.[102]  
All in all, these glycoconjugates can be considered as pro-drugs that release copper 
chelators only in the reducing intracellular medium of hepatocytes. 
Reduction of the copper uptake by an indigestible biopolymer 
Another promising therapy can be if an efficient copper chelator is grafted to an 
indigestible carrier. A system like this can bind copper ions obtained by food in the gastro 
intestinal tract and hereby reduces the amount of the absorbed copper ions. Meanwhile, the 
chelator does not enter the blood stream or other organs and therefore it does not induce side 
effects. Cu(II) complexes of 8-hydroxyquinoline are formed in a wide pH range. 
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Furthermore, the ligand displays high selectivity for Cu(I) ions over Zn(II). 8-
hydroxyquinoline was covalently bound to microcrystalline cellulose and crosslinked 
chitosan. The covalent bond prevents the release of the ligand in the body. These 
biopolymers are non-digestible, because human body lacks the cellulolytic enzymes and thus 
they go through the body without degradation or reaction with bio-compartments and 
therefore they are supposed to be harmless.[103] 
α-lipoic acid, as a new candidate 
Recently, α-lipoic acid (Figure 19) was proposed as a new drug candidate for the 
treatment of Wilson’s disease.[66]  
 
Figure 19. Schematic structure of α-lipoic acid 
This compound is an essential cofactor of several enzymes that participate in aerobic 
metabolism. It mainly acts by transferring acyl or methylamine groups. α-lipoic acid has 
some advantageous features with regard to the treatment of WD. α-lipoic acid is reduced in 
the intracellular environment to dihydrolipoic acid, which has two free thiol groups and 
displays higher affinity for Cu(I) than D-Pen or trien. α-lipoic acid has good membrane and 
blood brain barrier permeation ability. Finally, it is a well-tolerated food supplement. 
Preliminary experiments on hepatic cells showed that α-lipoic acid could protect the cells 
from a copper concentration 1,5x higher than its LD50 value. 
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III. Aims and Objectives 
Due to the drawbacks of the currently used drugs, there is a substantial need of new 
copper chelators for the treatment of Wilson’s disease. In chapter 3.2 a new strategy was 
described where excess Cu(I) in hepatocytes is targeted. To improve the efficiency of the 
chelators, it is necessary to identify the factors that play a role in the affinity towards Cu(I). 
Peptides are easily tunable tools in metal ion chelation thanks to the diverse functional 
groups of the essential amino acids. In peptide design aiming at the chelation of the soft 
Cu(I) ion,[5] cysteines are obvious choices as potential binding sites. The goal of my PhD 
project was the design of new, cysteine-containing peptides as potential drug candidates and 
the investigation of their Cu(I) binding properties. 
Three series of peptides were designed from three different approaches. 
1) Peptides mimicking the metal binding loop of the bacterial Cu efflux regulator 
protein (CueR) were chosen to take advantage of the outstanding sensitivity and 
selectivity of CueR. 
2) In three cysteine containing peptides we wanted to combine the advantageous 
features of the ligands previously developed in Pascale Delangle’s lab, namely 
the large Cu(I) binding affinity of tripodal pseudopeptides and the better 
internalization by the hepatocytes of peptide based molecules. 
3) Finally, the advantages of a highly preorganized peptide structure were exploited 
in a short, rigid tetrapeptide where two cysteines were linked by a turn motif 
The Cu(I) binding properties of these peptides were studied by solution equilibrium 
and structural methods, i.e. UV-visible, circular dichroism and nuclear magnetic resonance 
spectroscopies and mass spectrometry to evidence the influence of the peptide length, the 
amino acid sequence, the backbone structure and the number of the Cys residues on Cu(I) 
complexation properties in water at physiological pH. Complexes with Hg(II), a soft divalent 
ion often taken as a model non redox-active metal ion for Cu(I), have also been studied for 
comparison. Since Zn(II) is present in relatively high concentration in the body and it is a 
potential competitor of Cu(I), the interaction with Zn(II) was therefore also tested. 
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IV. Experimental section 
1. Peptide synthesis and purification 
The peptides were synthesized by solid phase peptide synthesis (SPPS) following the 
Fmoc strategy. The application of SPPS was established by Robert B. Merrifield in 
1963.[104] In this protocol, the growing polypeptide chain is attached to a solid support 
during the whole synthesis, and therefore the reagents and by-products are easily removable 
by simple filtration and washing. Over the years, SPPS underwent several optimization in 
the solid support, the protecting groups, etc. to reach its present state.[105] The protocol 
consists of the repeating cycles of deprotection/washing/coupling/washing/capping/washing 
as graphically summarized in Figure 20. The peptide chain grows from the C-terminus to 
the N-terminus, contrary to the protein synthesis in vivo. The amino acid building blocks are 
protected by the base labile 9-fluorenylmethyloxycarbonyl group (Fmoc) at the amino 
function and by different acid labile protecting groups at the side chains. 
 
Figure 20. The main steps of the Fmoc solid phase peptide synthesis 
For the synthesis of linear peptides Rink Amide AM resin (200-400 mesh) was used 
as solid support with 0.67 mmol/g loading, which gives an –NH2 protected C-terminal 
function after cleavage. The first step of the cycle, after swelling the resin in NMP (N-
Methyl-2-pyrrolidone), was the removal of Fmoc by 20% piperidine solution in NMP for 
3+3+10 minutes. The coupling mixture contained 4 times excess of amino acid building 
block, HOBt (Hydroxybenzotriazole), HBTU (2-(1H-benzotriazol-1-yl)-1,1,3,3-
tetramethyluronium hexafluorophosphate) and 8 times excess of DIPEA (N,N-
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Diisopropylethylamine) in NMP. The reaction time was 1h. The incomplete coupling was 
checked by Kaiser’s test using phenol, pyridine and ninhydrin solutions.[106] After each 
coupling, the resin was treated with the mixture of 10 % (in volume) acetic anhydride and 
10 % DIPEA in dichloromethane (DCM) to acetylate the unreacted amino groups (2×1ő 
min), this is called as capping. These steps were repeated until the peptide reached the 
desired sequence. After the last amino acid coupling, the Fmoc group was removed and the 
free amino groups were acetylated as described above. Then the resin was washed by DCM 
and MeOH and dried in a dessicator. 
The protecting groups of the side chains and the peptide from the resin were cleaved 
in one step by the mixture of 92% TFA (trifluoro acetic acid), 1% TIS (triisopropylsilane), 
2.5% EDT (ethanedithiol), 2.5% water and 2% phenol. After 4h of reaction, the mixture was 
filtered and TFA was removed by evaporation. The cleaved peptide was precipitated in ice 
cold ether and then centrifuged with 6000 rpm for 15 min. The step of washing with ether 
was repeated two more times. The crude product was lyophilized. 
Side chain protected linear precursors of the cyclic peptides were synthesized on pre-
loaded H-Gly-2-Cl-trityl (0.54 mmol/g, 0.5 g) resin following the same protocol. The 
cleavage of the peptide from this resin leaves the C-terminus free (acid form) to enable the 
cyclization. The precursor was cleaved from the resin by TFA in DCM (1/99 v/v) in a short 
time (2×5 min) in order to avoid the deprotection of the side chains. The filtrate was 
neutralized in MeOH/pyridine 8/2. After filtration, evaporation and precipitation, the 
product was dissolved in DCM in 0.5 mM concentration. A mixture of 3 equiv. of PyBOB 
(benzotriazol-1-yl-oxytripyrrolidinophosphonium hexafluorophosphate) and 4 equiv. of 
DIPEA was added, and stirred for 2h. DCM was removed by evaporation followed by 
precipitation and centrifugation. Then the product was treated in the same way like described 
before to cleave the protecting groups and obtain the crude product. 
The products were purified by reversed phase HPLC on a Shimadzu LC-20 
instrument equipped with a Phenomenex Synergi 4 μm fusion-RP 80 Å semi-preparative 
column using H2O and acetonitrile eluents containing 0.10% TFA at 3 mL/min flowrate. 
ESI-MS and analytical RP-HPLC using an analytical column (Chromolith® performance 
RP-18e 100-4.6 mm) at 1 mL/min flowrate (gradient 0-60% of AcN in 30 min) were 
performed to check the purity. For the detailed description of the synthesis and the analytical 
data of EC, VC and HS peptides see reference [107, 108] and of P3C see [109]. The 
references of the 3 cysteine containing and the tetrapeptides are summarized in Table 1. 
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Table 1. Analytical HPLC and (+) ESI MS references of the studied peptides 
Name tr (min) 
Chemical 
formula 
Molecular 
weight 
(g/mol) 
m/z 
[M+2H]2+ 
m/z  
[M+H]+ 
1L 10.5 C36H62N14O14S3 1010.37 506.3 1011.4 
1C 10.7 C34H57N13O13S3 951.34 476.8 952.3 
2L 10.4 C36H62N14O14S3 1010.37 506.7 1011.4 
2C 10.9 C34H57N13O13S3 951.34 476.7 952.3 
3C 10.8 C37H62N14O14S3 1022.37 512.3 1023.3 
CDPPC 14.3 C18H29N5O5S2 460.2 − 460.2 
CPGC 10.0 C15H25N5O5S2 420.1 − 420.0 
2. Sample preparation for physicochemical studies 
Solution of the peptides 
Cysteine containing peptides and Cu(I) are sensitive to oxidation, therefore all the 
sample manipulations were performed in a glovebox under inert atmosphere and the solvents 
were degassed with argon. Peptide solutions were freshly prepared for each experiment in 
the appropriate buffer solution. When experiments with Cu(I) were performed, the peptide 
solution was prepared in the presence of acetonitrile (10% in volume) to overcome the 
disproportionation of Cu(I) in water.[110] The final peptide concentration was determined 
by Ellman’s procedure, based on the reaction of DTNB (5,5-dithio-bis(2-nitrobenzoic acid)) 
with the free thiols forming TNB (2-nitro-5-thiobenzoate) (Figure 21), which has intensive 
absorption at λ = 412 nm with 412nm = 14 150 M−1cm−1.[111, 112] 
 
Figure 21. Reaction between DTNB and the free thiols 
According to the protocol, 2.5 mL of phosphate buffer (100 mM, pH = 7.25) was transferred 
to a UV cell (l = 1 cm) and 200 μL of DTNB solution (~ 10 mM) in the same buffer was 
added (V0) and the absorbance was recorded at λ = 412 nm (A0). After the addition of x mL 
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aliquot of the peptide solution (Vpeptide), the absorbance was recorded again at the same 
wavelength (A1). The concentration was determined according to the following equations. 
�� = − �� + � �∙ �  � � =  ��� ∙ � + � �� �  
c
SH
: concentration of free thiols 
n: number of thiols 
Solutions of the metal ions 
Cu(I) solution (c ~ 3 mM) was prepared from Cu(CH3CN)4PF6 in acetonitrile. The 
final concentration was determined by adding BCS (bathocuproin disulfonate) in excess and 
measuring the absorbance of the [Cu(BCS)2]
3− complex ( 483nm = 13 300 M−1cm−1).[20] 1.8 
mL of phosphate buffer, 20 mM, pH = 7.4 was transferred to a UV cell (l = 1 cm) and 200 
μL of BCS solution (c ~ 10 mM) in the same buffer was added (V0). The absorbance was 
measured at λ = 483 nm (A0,). Then x mL aliquot of the metal solution (VCu(I)) was added 
and the absorbance was recorded again (A1, λ = 483 nm). The concentration was determined 
according to the following equation. 
� = − �� + �∙ � ∙ � + ��  
Zn(II) and Hg(II) solutions (c ~ 3 mM) were prepared from precise weights of ZnCl2 
and HgCl2, respectively, dissolved in water. 
Solutions of the competitors used for determining the stability constants of the metal-
peptide complexes 
BCS and BCA (bicinchoninate anion) solutions (c ~ 10 mM) were prepared by 
dissolving appropriate amounts of sodium bathocuproin disulfonate or sodium 
bicinchoninate, respectively, in phosphate buffer (20 mM, pH =7.4). For the determination 
of the concentration of these solutions, they were first diluted by 100 times in the same buffer 
and then titrated by a Cu(I) solution with known concentration (c ~ 3 mM). The plot of the 
absorbance at 412 nm as a function of the volume of the added Cu(I) solution gave two 
straight lines and the intersection point (Veq) indicated the total formation of the ML2 
complex. The concentration was then calculated according to the following equation. 
45 
� =  ∙ � ∙ ��  
The zincon solution (c ~ 3 mM) was prepared by dissolving zincon monosodium salt 
in DMF. The concentration was similarly determined as above. After a 100× dilution in 
HEPES buffer, the sample was titrated by a Zn(II) solution with known concentration (c ~ 3 
mM). The plot A620nm = f(VZn(II)) gave the two straight lines and from the intersection point 
(Veq) the concentration could be easily calculated according to the following equation. � =  � ∙ ����  
Iodide solutions (c ~ 0.01 M, 0.1 M and 0.5 M) were prepared by dissolving precise 
weights of KI in water. 
3. UV-visible spectroscopy 
UV-vis spectra were recorded on a Varian Cary50 spectrophotometer equipped with 
optical fibers connected to an external cell holder in the glovebox. Generally, 2.5 mL freshly 
prepared peptide solution in phosphate buffer (cpeptide ~ 30 μM, cbuffer = 20 mM, pH = 7.4) 
was transferred into a quartz optical cell with 1.0 cm path length (Hellma Analytics). Then 
aliquots of the appropriate metal solution (c ~ 3 mM) were added corresponding to 0.1 
equivalents. In case of the 3 Cys containing decapeptides, titration with Cu(I) was performed 
in independently prepared samples due to long equilibration times. Aliquots of the Cu(I) 
solution corresponding to 0.0-3.0 equivalents were added to the peptide solutions. Samples 
were equilibrated for at least 2 h. Spectra were recorded regularly until stabilization. 
For pH titrations 2.0 mL of the peptide solution (c ~ 30 μM) was transferred into the 
quartz UV cell and then 0.9-1.0 equivalent of a metal ion was added. The desired pH values 
were adjusted with KOH and HCl solutions of appropriate concentrations (e.g. 0.1 M, 0.01 
M). The pH was measured by a Metrohm 702 SM Titrino system equipped with a Mettler 
Toledo InLab ® Microelectrode. 
4. CD spectroscopy 
CD spectra were acquired on an Applied Photophysics Chirascan spectrometer. The 
instrument was calibrated with (1S)-(+)-10-camphorsulfonic acid. The spectra were 
recorded in the 190-400 nm wavelength range with 1 nm steps and a dwell time of 2 s per 
points. Data were acquired and treated by Pro-Data and Pro-Data Viewer programs (Applied 
Photophysics). For each sample 3 parallel spectra were recorded and the average of these 
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spectra were smoothed. CD spectra are reported in molar ellipticity ([Θ] in units of deg cm2 
dmol−1). [Θ] = obs/(10lc) where obs is the observed ellipticity in millidegrees, l is the optical 
path length in cm and c is the peptide concentration in mol/dm3. Generally, 2.5 mL freshly 
prepared solution in phosphate buffer (cpeptide ~ 30 μM, cbuffer = 20 mM, pH = 7.4) were 
transferred into a quartz optical cell with 1.0 cm path length (Hellma Analytics). Then 
aliquots of the Cu(I) solution (c ~ 3 mM) were added corresponding to 0.25 equivalents. 
Titrations of the 3 Cys containing decapeptides with Cu(I) were performed in the same batch 
samples as described above for the UV titrations. 
5. NMR spectroscopy 
NMR experiments were performed on Bruker Avance 400 MHz and 500 MHz 
spectrometers equipped with 5 mm inverse broadband probes with Z-gradients. For spectrum 
acquisition and evaluation TopSpin 3.2 program was applied. All sample manipulations 
were performed in the glovebox. Peptide concentration was ~ 1 mM. Samples were 
transferred into tubes with J. Young screwcap to avoid contact with air. 
Assignment of the resonances in CDPPC and CPGC peptides 
Complete assignment of the proton resonances in the free and Cu(I) bound peptides 
were achieved by the combination of COSY, TOCSY, NOESY and ROESY experiments. 
Samples for NMR spectroscopic measurements were prepared in phosphate buffer in D2O 
(20 mM, pD = 7.4). Amide protons were identified on the spectra recorded for the samples 
prepared for the determination of the temperature coefficient as described later. 
Cu(I) titration 
1H NMR spectra were recorded at 298 K in a 12 ppm window size and 32k time 
domain. Peptide solutions were prepared in phosphate buffer in D2O (20 mM, pD = 7.4) 
titrated with a Cu(I) solution in CD3CN (c ~ 30 mM). 
Diffusion coefficient measurement 
Diffusion coefficient measurements were performed using the bipolar stimulated 
spin echo sequence (PGSE).[113-115] Diffusion coefficients were obtained by TopSpin 3.2 
using the following equation: � = �  exp − √ � �� ∆ − � , where I and I0 are the 
intensities detected with and without gradient pulses of strength gi, respectively The length 
of the bipolar gradient pulse is is the diffusion delay, and is the gyromagnetic ratio 
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(for protons, H = 4 258 Hz/G). ms and  = 2 ms values were used in the diffusion 
coefficient measurements. In the experiments, g was incremented from 2.31 to 43.81 G/cm. 
Temperature coefficient measurement 
The temperature coefficient of the amide protons of the free ligands and the Cu(I) 
complexes were measured by recording 1H NMR spectra over the temperature range 278-
318 K. Temperature coefficients of the free peptides were compared by recording the spectra 
in H2O/D2O, 9/1, v/v. The spectra of the Cu(I) complexes were recorded in phosphate buffer 
(20 mM, pH = 7.4, H2O/D2O, 9/1, v/v). Residual water signals were suppressed by 
presaturation. 
6. ESI MS experiments 
Mass spectra were acquired on a LXQ-linear ion trap (THERMO Scientific) 
instrument equipped with an electrospray source. Electrospray full scan spectra in the range 
of m/z = 50-2000 amu were obtained by infusion through a fused silica tubing at 2-10 
µL/min. The samples were analyzed in the negative mode. The LXQ calibration (m/z = 50-
2000) was achieved according to the standard calibration procedure from the manufacturer 
(using a mixture of caffeine, MRFA and Ultramark 1621). The temperature of the heated 
capillary for the LXQ was set in a range of 200-2ő0 °C, the ion-spray voltage was adjusted 
to 3-6 kV and the injection time varied between 5-200 ms. The ligand solution (c ~ 100 µM) 
was prepared in ammonium acetate buffer (pH = 7.0, cbuffer = 20 mM). Samples for Cu(I) 
experiments contained 10% of AcN in volume. Different equivalents of the appropriate 
metal ion solution (c ~ 3 mM) were added to the peptide samples. 
7. Determination of stability constants 
Stabilities of the metal complexes at given pH values were determined in the presence 
of well-known competitors. The displacement of the metal ions from their peptide complexes 
by the competitor, or the reverse, was followed by UV spectroscopy in all cases. 
Stability of copper(I) complexes 
Two competitors, namely BCS (bathocuproin disulfonate) and BCA (bicinconinate 
anion), presented in Figure 22, were used depending on the stability of the studied Cu(I)-
peptide complex. 
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Figure 22. Schematic structure of the competitor BCS and BCA 
Both of these ligands form CuL2 complexes with known stability and spectroscopic 
properties. [20] 
 Cu+ + 2 BCS2− ⇌ [Cu(BCS)2]3− logβ2 = 19.8 
 Cu+ + 2 BCA2− ⇌ [Cu(BCA)2]3− logβ2 = 17.2 
[Cu(BCS)2]
3− is an orange complex with absorption maximum at λmax = 483 nm and  = 
13 300 M−1cm−1. The purple [Cu(BCA)2]
3− has maximal absorption at λmax = 562 nm 
maximally with  = 7 900 M−1cm−1. 
Different strategies were applied depending on the characteristics of the studied 
system. In the first attempt, parallel samples were prepared by adding 0.9 equiv. of Cu(I) to 
2.5 mL of the peptide solution in phosphate buffer (cpeptide ~ 30 μM, cbuffer = 20 mM, pH = 
7.4). After the formation of the Cu(I)-peptide complex, different amounts of the appropriate 
competitor were added. Samples were equilibrated until the absorbance stabilised. The 
calculation of the stability constants was based on the measured absorbance at the 
wavelength where the absorption is maximal according to the following equations. Charges 
are omitted for simplicity. [ � � ] =  [ �] = � � − [ � � ] [ �] = [ � � ]. [ �]  [ ��] = � − [ � � ] − [ �] [�] = �� − [ ��] = [ ��][ �][�] 
A reverse another strategy was applied in case of CDPPC and CPGC peptides. The 
[Cu(BCS)2]
3− complex was titrated with the peptide solution. Samples, which were prepared 
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in phosphate buffer (20 mM, pH = 7.4), contained Cu(I) in c ~ 30 μM concentration and 
BCS in 10-fold excess. Then aliquots of peptide solution were added. Samples were 
equilibrated until the stabilization of the absorbance. The recorded spectra were fitted with 
SpecFit program to obtain the apparent stability constant.[116-119] 
Stability of mercury(II) complexes 
Stabilities of the mercury(II) complexes were determined by competition with I− 
ions. Mercury(II) forms consecutively four iodo complexes with known stabilities. Data 
presented in Table 2 were determined at I = 0.5 M ionic strength.[120] In our application 
these stability constants were recalculated to I = 0.1 M by the SIT model.[121, 122] 
Table 2. Stability constants of the Hg(II) – I− complexes previously determined at I = 0.5 M ionic strength 
and the data recalculated for the applied conditions. 
 
log 
(I=0.5 M)[120] 
log 
(I=0.1 M) 
[HgI]+ 12.87 13.05 
[HgI2] 23.82 24.09 
[HgI3]
− 27.60 27.84 
[HgI4]
2− 29.83 29.91 
As a first step, the molar absorption spectra of the Hg(II)-iodo complexes were 
determined under the conditions used in the subsequent competition with the peptides. Hg(II) 
solution (c ~ 30 μM, I = 0.1 M NaClO4) were transferred to a UV cell. The pH was adjusted 
to 2.0 by a 1.0 M HCl solution. The pH was controlled throughout the whole titration. This 
Hg(II) sample was titrated with KI solution (c ~ 0.01, 0.1; 0.5 M). The recorded spectra were 
fitted with SpecFit [116-119] where the stability constants were fixed to values given in 
Table 2. 
Afterwards, 1.0 equivalent of Hg(II) was added to 2.0 mL of the peptide solution (c 
~ 30 μM, pH = 2.0, I = 0.1 M NaClO4). This sample was then titrated with KI solution. In 
the fitting procedure the stabilities and the molar absorption spectra of the Hg(II)-I− 
complexes were fixed. 
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Stability of zinc(II) complexes 
The apparent stability constants of the Zn(II) complexes were determined in the 
presence of zincon (ZI) as a competitor (ZnZI logβ11 = 4.9, 620nm = 23 200 M−1cm−1) by UV-
vis spectroscopy.[123] 
 
Figure 23. The schematic structure of zincon 
The peptide solution was prepared in ca. 30 μM concentration in HEPES (Ő-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) buffer (cbuffer = 20 mM, pH = 7.4) and 1.0 
equiv. of Zn(II) was added. The Zn(II)-complexes were then titrated with zincon solution (~ 
3 mM in DMF). The stability of the absorbance at λ = 620 nm was controlled before any 
further addition. The stability constants were calculated by considering the exclusive 
formation of a mononuclear complex according to the following equations. [����] =  [��] = �� − [����] [��] = [����]. [��] [���] = ��� − [����] − [��] [�] = �� − [���] = [���][��][�] 
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V. Results and Discussion 
1. Cu(I) binding properties of model peptides of the metal binding loop of CueR 
proteins 
1.1. The background of the chosen peptide sequence 
The copper efflux regulator CueR protein [124-126] is a transcriptional factor and it 
belongs to the MerR family of metalloregulatory proteins.[127-130] It regulates the 
expression of proteins which take part in copper detoxification in bacteria. CueR is able to 
sense Cu(I) in zeptomolar (10−21 M) concentration and distinguishes +1 charged metal ions 
from +2 charged ones. The metal binding loop of CueR from E. coli is presented in Figure 
24. As it is seen, the Cu(I) ion is coordinated by two cysteine residues, which are conserved 
throughout the MerR family, in linear geometry. This coordination geometry is rarely 
observed in protein metal binding sites but therefore it can be rather suitable for selective 
metal ion recognition.[131, 132] 
 
Figure 24. The metal-binding region in CueR [131] 
To exploit the selectivity and sensitivity of CueR in Cu(I) chelation, peptides were 
designed to mimic the metal binding domain of this protein from different bacteria. 
Figure 25 presents the schematic structures of the studied peptides. Two of them are 
identical to the native sequence of CueR in bacteria E. coli (Ac-ACPGDDSADCPI-NH2; 
EC) and V. cholerae (Ac-SCPGDQGSDCPI-NH2; VC). The third one (Ac-
SCHGDQGSDCSI-NH2; HS) is the variant of VC where the prolines were replaced by a 
histidine and a serine to modify the flexibility and as well the metal binding properties of the 
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molecule. Indeed, histidine and proline can be found at the same positions in some other 
MerR family member proteins.[131] 
 
Figure 25. Schematic structures of the CueR model peptides 
HS was demonstrated to be able to accommodate Cd(II), Hg(II) and Zn(II), which 
are metal ions with significantly different coordination preferences. HS formed a variety of 
species with Cd(II) depending on the pH and the metal ion availability.[133] Hg(II) was 
bound to the two cysteine residues of the peptide forming a loop-like structure. In contrast, 
in Zn(II) ligation the histidine moiety also participated in metal ion binding besides the 
cysteine thiolates, providing a more structured form of the peptide backbone with higher 
helical content.[134] Interestingly, EC and VC bound Ag(I) by a protonated thiol with a pKa 
close to physiological pH. [108] Despite of the similar chemical characteristics of Ag(I) and 
Cu(I), the behavior of the peptides with Cu(I) cannot be predicted and therefore the study of 
the Cu(I)-EC/VC/HS systems is inevitable. 
1.2. Mononuclear Cu(I) complexes of the CueR mimicking peptides 
The interaction between Cu(I) and EC, VC, HS peptides was first studied by UV-vis 
spectroscopy. Aliquots of Cu(I) solution corresponding to 0.1 equivalent per ligand were 
added to the peptide solutions at pH = 7.4. As it can be seen in Figure 26, the increasing 
Cu(I) concentration results in the appearance of intense absorption bands at λ ~264 nm and 
λ ~300 nm. The first transition is characteristic for the charge transfer from thiolate to Cu(I) 
(LMCT) [133] indicating that the metal ion is coordinated to the ligand by the cysteine 
moieties.  
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Figure 26. UV titration of EC (A), VC (B) and HS (C) peptides with Cu(I) at pH = 7.4 (phosphate buffer, 20 
mM). The insets show the evolution of absorbance as a function of the cCu(I)/cpeptide ratio. (cpeptide = 30 µM) 
The LMCT absorbance increases linearly in case of VS and HS, while in the titration 
of EC follow a non-linear trend. Lebrun and co-workers studied the Cu(I) binding of the 
CopZ protein [135] and observed a similar non-linear trend with intersections at 0.5 and 1.0 
Cu(I) equivalents. The formation of two major forms of Cu(I)-CopZ complex was proposed. 
From 0.0 to 0.5 Cu(I) equivalent two protein bound one Cu(I) ion via one cysteine of each 
molecule. Between 0.5-1.0 equivalent, Cu(I)2(CopZ)2 formed where four cysteines took part 
in the Cu(I) coordination and two of them bridged the two metal ions. The formation of these 
two Cu(I)-CopZ complexes was more evident in the CD spectra, where two clear breakpoints 
were observed in the evolution of the LMCT bands. 
A competition between Cu(I) and Hg(II) was conducted to determine whether the 
EC peptide forms a similar CuP2 complex. A sample containing EC and 0.5 equivalent of 
Cu(I) was titrated with Hg(II). The RS− to Cu(I) LMCT does not change significantly until 
0.5 equivalent of Hg(II) is (Figure 27). Since the more thiophilic Hg(II) does not disturb the 
RS− to Cu(I) LMCT, there must be free cysteines available to coordinate the added Hg(II) 
ions. The slight increase observed at 264 nm can be attributed to the overlapping effect of 
the RS− to Hg(II) LMCT below 220 nm.[17, 74, 134, 136-138] Further addition of Hg(II) 
results in the collapse of the RS− to Cu(I) LMCT and the continuous increase of the Hg(II) 
LMCT indicates the transformation of the Cu(EC) complex into the more stable Hg(EC) 
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species. Based on these observations it can be stated that the CuS4 type Cu(EC) complex 
does not exist. 
 
Figure 27. UV titration of the sample containing EC and Cu(I) in 1:0.5 ratio with Hg(II) at pH = 7.4 
(phosphate buffer, 20 mM). The inset shows the evolution of the absorbance at 26Ő (•) and 220 () nm as a 
function of the cHg(II)/cEC ratio. (cpeptide = 30 µM) 
Molar absorbances of the LMCT  ~ 7000 M−1cm−1 per bound Cu(I) were calculated 
as the slope of the absorbance according to the Cu(I) concentration. This value is compatible 
with those determined for metallothioneins [28, 29] or other Cys containing ligands.[75, 
100] The increase of the absorbance was terminated by a sharp breakpoint at 1.4 Cu(I) 
equivalents. Previously it was shown that the LMCT is not sensitive for the speciation only 
for the number of thiolate to Cu(I) bonds.[34] With these ligands the absorbance increase 
linearly up to 2.0 equivalents of Cu(I), even though it was demonstrated that two different 
species formed, the CuL mononuclear complex from 0.0 to 1.0 Cu(I) equivalent and Cu4L3 
or Cu6L3 clusters in excess of Cu(I). 
The lower energy band at λ ~ 300 nm was previously attributed to cluster formation 
in metallothioneins.[28] However it was also observed with other two cysteine containing 
peptides, where the exclusive formation of mononuclear complex until 1.0 Cu(I) equivalent 
was proved by DOSY NMR.[74] 
CD spectroscopy was also applied to monitor the effects of the gradual addition of 
0.25 equivalent of Cu(I) into the peptide solutions. The results are presented in Figure 28. 
The intense negative band below 220 nm is attributed to π → π* and possibly overlapping n 
→ π* transitions of the amide bonds of the peptide backbone [34, 139] displaying an 
essentially disordered structure.[107, 134, 140] The gradual change of this band illustrates 
well the structural rearrangement promoted by Cu(I) binding. Besides, CD spectroscopy also 
gives information about the RS− to Cu(I) LMCT bands. Along with the increasing Cu(I) 
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concentration, CD bands appear in the  = 2Ő0-380 nm wavelength range. For all the three 
peptides the intensity of these bands increases linearly up to 1.0 equivalent of Cu(I) and 
isodichroic points are systematically observed. 
 
Figure 28. CD titration of EC (A), VC (B) and HS (C) peptides with Cu(I) from 0.0 (a) to 1.0 (b) 
equivalents (solid lines) at pH = 7.4 (phosphate buffer, 20 mM). Dashed lines represent spectra with 1.25 (c) 
and 2.0 (d) equivalents of Cu(I). The insets show the evolution of absorbance as a function of the cCu(I)/cpeptide 
ratio. (cpeptide = 30 µM) 
These results clearly demonstrate the transformation of the free peptides into one 
single complex species up to reaching the 1:1 Cu(I):peptide ratio. In other words, only the 
CuP mononuclear complexes formed with all the three peptides, even in case of EC where 
a more complicated complex formation occurring in different steps was suspected based on 
the slight bend in the UV titration. 
The comparison of the CD spectra of the three peptides in the presence of 1.0 
equivalent of Cu(I) (highlighted in green in Figure 28) reveals that the Cu(HS) complex has 
a significantly different CD signature. Since the spectra of the free peptides are quite similar 
and the difference mainly emerges in the LMCT region, the Cu-thiolate interaction is 
somehow affected in Cu(HS) compared to the Cu(I) complexes of the two other peptides. 
The absence of the proline residues and the higher conformational flexibility in HS could 
explain this difference. However, the most likely explanation is the participation of the 
histidine residue in Cu(I) coordination, as it was demonstrated earlier for a few Cu(I)-binding 
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proteins and model peptides.[9, 10, 141, 142] The additional coordinating donor group 
besides the thiolates should modify the chiral environment around the Cu(I) and thereby the 
RS−-Cu(I) LMCT leading to a different shape of the CD spectrum. 
(−)ESI MS spectra were also recorded for additional information about the complex 
speciation. The most intense signals arise from the free ligand as the negatively charged 
[P−2H]2− and [P−H]− ions (Figure 29). Mononuclear CuP complexes are also clearly 
observed with all the three peptides when 0.9 equivalent of Cu(I) is added. They are detected 
in the form of [P−3H+Cu]2− with m/z = 631.4 (Cu(EC)), 639.2 (Cu(VC)), and 654.1 
(Cu(HS)). Cu(EC) and Cu(HS) complexes are also observed as monocharged species 
[P−2H+Cu]− with m/z = 1264.2 and 1309.2, respectively. 
 
Figure 29. (−)ESI-MS spectra of the studied peptides in the presence of 0.9 equivalent of Cu(I) at pH = 6.9 
(NH4AcO buffer, 20 mM) with the experimental and theoretical isotopic patterns of the detected species. * 
indicates sodium adducts, • indicates peaks related to oxidized species. (cpeptide = 100 μM) 
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1.3. Polynuclear Cu(I) species evidenced in excess of the metal ion 
When more than 1.0 equivalent of Cu(I) is added, the complex formation becomes 
rather complicated. In the presence of Cu(I) excess, a third transition emerges in the UV 
spectra at λ ~ 340 nm representing a formally spin-forbidden 3d→Ős metal to metal transition 
[28, 143] and indicating the formation of often-observed Cu(I)-thiolate clusters.[11, 75, 143, 
144] The intensity of the LMCT bands in the UV spectra continue to increase up to 1.4 
equivalents of Cu(I). However, the clear breakpoint at 1.0 Cu(I) equivalent observed in the 
CD titrations confirm that the LMCT is not sensitive to the nature of the different complexes 
(monometallic or polymetallic) but only to the number of the thiolate-Cu(I) bonds. 
The CD spectra undergo significant changes when more than 1.0 equivalent of Cu(I) 
is added as represented by dashed lines in Figure 28. This indicates a rather complicated 
speciation, as a possible result of the formation of different clusters or polymetallic 
structures. 
Figure 30 presents the (−)ESI MS spectra recorded for samples of the peptides with 
2.0 equivalents of Cu(I). Several polynuclear species like Cu2P, Cu3P or Cu4P2 can be 
observed in all the three systems. 
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Figure 30 (−)ESI-MS spectra of the studied peptides with 2.0 equivalents of Cu(I) at pH = 6.9 (NH4AcO 
buffer, 20 mM) with the experimental and theoretical isotopic patterns of the detected species. • indicates 
peaks related to oxidized species. (cpeptide = 100 μM) 
1.4. Confirmation of the participation of the histidine residue in Cu(I) coordination by 1H 
NMR spectroscopy 
The Cu(I)-coordination of the histidine residue in the HS peptide was suspected on 
the basis of the CD spectroscopic results. To obtain more information 1H NMR 
measurements were conducted. Solution of HS was titrated by Cu(I) from 0.0 to 2.0 
equivalents with 0.25 steps. The aromatic region of the recorded spectra is shown in Figure 
31. As the results of the Cu(I) addition, the narrow C 1H and C 2H signals of His are shifted 
to higher ppm values and new, broad signals appear. These findings clearly show that the 
His residue is involved in Cu(I) binding. However, the two different type of effects suggest 
different complex formation processes. The downfield shift of the C 1H and C 2H resonances 
can be attributed the formation of the Cu(HS) mononuclear complex and these signals vanish 
in the presence of Cu(I) excess. Dynamic exchange between several species at the NMR 
timescale can lead to the broadening of the signals indicating the presence of polynuclear 
species. They can be seen even at low Cu(I) concentration, where the CD and MS 
experiments proved the formation only of the 1:1 complex up to 1.0 Cu(I) equivalent. 
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Nevertheless, the concentration applied in the NMR experiments (mM) is significantly 
higher than those used in other spectroscopic technics (30-100 µM) and the formation of 
polymetallic species is therefore strongly favored. 
 
Figure 31. 1H NMR resonances of the imidazole ring of the His residue in the HS-Cu(I) system in phosphate 
buffer in D2O (20 mM, pD = 7.4). (cHS = 1.5 mM) 
1.5. Effect of the pH on the coordination of the cysteine thiols 
UV-vis spectra of the peptides in the presence of 0.9 equivalents of Cu(I) per ligands 
were also recorded as a function of pH. As it can be seen in Figure 32, the absorbances 
attributed to the RS− to Cu(I) LMCT bands are stable above pH = 7 in all the three studied 
system and the  ~ 7 000 M−1cm−1 values showed that the complex formation is complete. 
 
Figure 32. Absorbance recorded at  = 264 nm in the Cu(I):peptide 0.9:1 systems as a function of pH. The 
continuous lines represent the fitted values for the same wavelength. Data fitting was performed by SpecFit 
in the wavelength range of  = 250-400 nm based on a simple model involving two Cu(I)-promoted thiol 
deprotonation processes. (cpeptide = 30 µM) 
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The spectral changes observed with decreasing pH suggest two consecutive 
protonation steps. The data were satisfactorily fitted with two apparent pKa values with the 
computer program SpecFit according to the following equations. 
 CuL + H ⇌ CuLH ��� =  ��  
 CuLH + H ⇌ CuLH2 ��� =  ��  
Table 3. Apparent pKa values of the Cu(I)-peptide complexes. Experimental errors in the last digits are 
indicated in parenthesis. 
 pKa1 pKa2 
EC 3.0(1) 5.5(3) 
VC 1.3(2) 3.6(2) 
HS 1.8(1) 4.3(2) 
 
The first protonation steps take place with pKa2 values between 3.6 and 5.5 and result 
in half loss of intensity of the LMCT bands observed above pH = 7. This is consistent with 
the decoordination of one of the cysteines to give a Cu(I) complex with only one thiolate 
coordinating to the metal center. These apparent pKa values of the Cu(I) complexes are lower 
than those reported for the Ag(I) complexes of EC and VC.[108] (De)protonation occurs 
significantly below physiological pH and therefore it is probably not relevant in the bacterial 
copper sequestration of CueR protein. pKa1 values determined for the second protonation 
step are in the range of 1.3-3.0 and lead to the complete loss of the LMCT absorbance to 
form of the CuLH2 species with no thiolate bound to Cu(I). The latter species in acidic 
conditions may be low stability Cu(I) complexes in which the metal center is coordinated to 
other functions than thiolates, or may represent as well the total release of Cu(I) from the 
protonated ligands. 
1.6. Stability of the Cu(I) complexes at pH = 7.4 
The various spectroscopic technics applied for the characterization of the Cu(I) – EC, 
VC, HS systems demonstrated the CuP mononuclear complexes are the dominant species at 
pH = 7.4. Their apparent stabilities were determined in the presence of a well-characterized 
competitor. Previously studied peptide-Cu(I) complexes with two thiolate coordinating 
groups have stability in the range of logβ11 = 15-17 at physiological pH.[74, 100] Similar 
affinities were expected for our ligands as well and according to Wedd’s recommendation 
[20, 145] bathocuproin disulfonate (BCS) is an appropriate choice of competitor for 
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determination of stabilities around logβ11 ~ 17. ([Cu(BCS)2]3− logβ2 = 19.8). However, BCS 
turned out to be a too strong competitor in our systems and as Figure 33 shows only 2 
equivalents were enough to withdraw nearly 50% of Cu(I) from the peptide complexes. 
Therefore, the weaker competitor bicinchoninate anion (BCA) was used to obtain the 
apparent logβ11 values. Similarly to BCS, BCA forms the [Cu(BCA)2]3− complex but with 
lower stability constant (logβ2 = 17.2). 
 
Figure 33. Comparison of the efficiency of BCS and BCA in the withdrawal of Cu(I) from the Cu(EC) 
complex in phosphate buffer (20 mM, pH =7.4). (cEC ~ 6ő μM, cCu(I) = 0.9 cEC) 
The addition of BCA resulted in the appearance of the intense absorption band 
centered at λ = 562 nm,  = 7 900 M−1cm−1 as Cu(I) was transferred to [Cu(BCA)2]3− from 
the CuP peptide complexes. The first indication on the magnitude of the affinities of the 
peptides towards Cu(I) is the number of BCA equivalents required for the 50% withdrawal 
of Cu(I). In case of EC only eight equivalents of BCA are enough for the 50% displacement, 
while with the two other peptides 16 (VC) and 24 (HS) equivalents are necessary, showing 
that affinity of the peptides for Cu(I) are in the order of EC < VC < HS. The calculated 
apparent stability constants are presented in Table 4. 
Table 4. Apparent stability constants of the Cu(I)-peptide complexes at pH = 7.4. Experimental errors in the 
last digits are indicated in parenthesis 
 � �� � �.� 
EC 15.3(1) 
VC 15.8(1) 
HS 16.3(1) 
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The lower stability of the Cu(EC) complex can be attributed to the charge repulsion 
between the negatively charged aspartate side chains. Similar effect was observed for other 
Cu(I) chelating ligands with negatively charged functional groups close to the CuS2− or 
CuS3− metal center.[76, 100] The somewhat higher affinity of the HS peptide may be the 
result of the missing prolines in the sequence, which makes this peptide more flexible to 
adopt an optimal geometry around Cu(I). Nevertheless, it is more likely that the contribution 
of the histidine in the coordination increases the stability of the complex. The Cu(I)-binding 
affinities obtained for the studied peptides are somewhat lower than those of the Atx1 model 
peptides incorporating the CxxC motif (logβ11pH7.4 = 17.4),[74] but compare well with more 
rigid cyclic decapeptides encompassing the CxxxxC motif (logβ11pH7.4 = 15.5-16.7).[100] 
This highlights that the affinity of peptide sequences with two cysteines for Cu(I) depends 
little on the flexibility of the loop and the number of amino acids between the two Cys 
residues. Therefore, the driving force for the coordination of the soft Cu(I) cation is expected 
to be mainly the formation of the two strong bonds with the soft thiolate donors. The stability 
constants determined in this study are very close to the affinity constant estimated for the 
Ag(I)-binding of VC (logβ11pH8.0 ~ 15–16), also by a competition experiment.[146] The 
comparison of the stabilities of the Cu(I) complexes with those determined previously for 
the Zn(II) complexes [108, 134] shows that these peptides display a large selectivity for 
Cu(I) vs. Zn(II). 
However, the Cu(I)-binding affinities of these peptidic models are 5–6 orders of 
magnitude lower than that of the native CueR protein.[21] This is a possible consequence of 
a loss of entropy upon metal ion binding of the models [27] but also the lack of other potential 
stabilizing effects, e.g. hydrophobic interactions in the metal binding pocket or the overall 
charge neutralization that operate in the protein in contrast to the models, exemplifying the 
complexity of metal regulation processes in vivo, which cannot simply be described by 
thermodynamic equilibria. However, the studied model peptides still resemble the ability of 
the protein to exclusively accommodate one metal ion under ligand excess conditions. 
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IN SUMMARY 
 similar Cu(I)-binding behavior of the three CueR model peptides  
 mononuclear CuL complex formation in physiologically relevant conditions 
 Cu(I)-coordinated via two Cys residues of the peptides and by the His of HS 
 formation of polynuclear species in the presence of Cu(I) excess 
 cysteine decoordination in two steps with decreasing pH, probably irrelevant in 
physiological Cu(I) sequestration 
 large affinities to Cu(I) at pH = 7.4, in the range of other 2-Cys peptides 
 similar affinity for Cu(I) and Ag(I), selectivity vs. Zn(II) 
 models cannot reproduce the affinity of the native CueR 
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2. Cu(I) and Hg(II) binding of cysteine-rich decapeptides 
2.1. Ligand design 
The highly efficient Cu(I)-binding metallothioneins coordinate Cu(I) usually 
trigonally [23, 24] therefore model peptides containing 3 cysteine residues can be interesting 
form the viewpoint of Cu(I) chelation. The increase of the number of cysteines hopefully 
increases the Cu(I) binding affinity as well. In this aspect, the beneficial features of the 
tripodal and peptidic ligands of the Delangle lab also can be potentially combined. As 
described earlier, three-cysteine-containing tripodal pseudopeptide ligands form well-
defined Cu(I) complexes with high stability, whilst peptide ligands are better internalized by 
hepatic cells.[102] The peptides studied in this chapter are presented in Figure 34. 
 
Figure 34. Schematic representation of the three-cysteine-containing peptides. The cysteine residues are 
highlighted in green and the bonds in the turn motif are indicated in bold. 
The sequences are based on the metal binding loop of the copper chaperone Atx1 
protein (MxCxxC). Investigation of the model peptide of this protein showed that although 
the methionine did not participate in the metal ion coordination, it was oriented towards the 
metal center.[74] Therefore the replacement of the Met residue by a Cys residue seemed to 
be an obvious choice to improve the metal binding properties in P3C peptide.[109] The 
positions of the cysteines in the sequences of linear and cyclic peptides were systematically 
varied in the CxCxC motif, which can be found also in metallothioneins.[23, 24] The β turn 
inducer xPGx motif was introduced next to the metal binding sequence in 1C and one amino 
acid apart from it in 2C to rigidify the peptide scaffold. Linear analogues 1L and 2L were also 
synthesized to study the effect of the flexibility/cyclization on the metal binding properties. 
Finally, an extra amino acid, an alanine was inserted in the sequence of 3C to determine 
whether a larger flexibility in the cysteine sidechain orientation is beneficial or not. 
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2.2. Copper(I) complexes: speciation 
Complex formation between Cu(I) ions and the peptides at pH = 7.4 was studied by 
UV-vis spectroscopy. During the titration of the peptides with Cu(I), the absorbances 
stabilized surprisingly slowly and the equilibrium was reached only after 2 hours. Such a 
long equilibration time was not observed before in similar three-thiolate-containing systems, 
neither in the case of simple nor complicated complex formation.[75-77] Therefore, samples 
were individually prepared by the addition of different equivalents of Cu(I) from 0.0 to 3.0 
to the solutions of the peptides with 0.25 or 0.5 steps to ensure enough time for reaching the 
thermodynamic equilibrium. This long equilibration time might be the first indication of a 
complicated complex formation. Since all the six peptides display similar behavior, the metal 
binding of the peptides will be demonstrated by the results obtained with 1C. The spectrum 
series recorded during the titration with Cu(I) is presented in Figure 35. The characteristic 
thiolate → Cu(I) LMCT band emerges around λ ~ 260 nm with increasing Cu(I) 
concentration. The absorbance increases linearly up to 2 equivalents of Cu(I) similarly to 
tripodal pseudopeptides encompassing 3 thiolates.[75-77] This breakpoint suggests the 
formation of polymetallic complex(es) with a (Cu2P)n overall stoichiometry. The molar 
absorptions  = 6-7000 M−1cm−1 per bound Cu(I) are in good agreement with previous 
results.[28, 75] 
 
Figure 35. UV titration of 1C with Cu(I) after 2h of equilibration at pH = 7.4 (phosphate buffer, 20 mM). The 
inset shows the evolution of the absorbance as a function of the cCu(I)/cpeptide ratio. (cpeptide = 30 µM) 
CD spectra were also recorded in the same individual samples. The LMCT bands (λ 
= 260-320 nm) appear as a result of Cu(I) addition (Figure 36), but the observed molar 
ellipticities ([Θ] = −2×104-1×104 deg cm−1 dmol−1) are relatively low compared to other 3-
thiolate systems ([Θ] = −Ő×104-8×104 deg cm−1 dmol−1).[75-77] The most affected region 
of the spectra falls in the λ = 220-240 nm wavelength range displaying bands that are 
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characteristic for the peptide backbone structure. This indicates that the complex formation 
induces structural rearrangements. More significant changes in the spectrum occur after the 
addition of 2.0 equivalents of Cu(I). The series of the spectra do not display any clear 
tendency. These results suggest that the complex formation is rather complicated and the 
free peptides transform into more than one complex species. 
 
Figure 36. CD titration of 1C with Cu(I) from 0.0 to 2.0 equivalents (left) and from 2.0 to 3.0 equivalents 
(right) after 2h equilibration time at pH = 7.4 (phosphate buffer, 20 mM). (cpeptide = 30 µM) 
On the recorded ESI-MS spectra of the peptides with 0.9 Cu(I) equivalents, the 
formation of polynuclear species like Cu4P3, Cu4P2 can be observed besides the mononuclear 
CuP complex (Figure 37). At higher Cu(I) concentration further species with higher 
nuclearity, Cu7P3 and Cu8P4 are also detected. 
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Figure 37. (+)ESI-MS spectra of 1C with 0.9 and 2.0 equivalents of Cu(I) at pH = 6.9 (acetate buffer, 20 
mM) with the experimental and theoretical isotopic patterns of the detected species. (cpeptide = 100 μM) 
The evolution of the UV spectra is seemingly simple because intensity of the thiolate-
Cu(I) LMCT band provides information only about the number of the Cu(I)-S bonds and not 
about the nature of the complexes. However, CD and ESI-MS results unambiguously show 
that the Cu(I) complex formation of the studied peptides is rather complicated and that many 
polymetallic species are present. 
The comparison of these Cu(I)-peptide systems to tripodal pseudopeptides 
incorporating three thiolates reflects that despite the similar evolution of the UV spectra, the 
Cu(I) complex formation is completely different with the two types of ligands. The tripodal 
ligands have a well-defined metal binding cavity stabilized by a network of intramolecular 
hydrogen bonds and this structure is able to control the speciation of the Cu(I) 
complexes.[75, 76, 79] The sharp contrast between the two groups of ligands can be related 
to their different structures. The three-cysteine-containing peptides seem to be too flexible 
to arrange the Cys sidechains in a metal binding cavity appropriate for accommodating one 
Cu(I) ion, and thus cannot control the speciation of Cu(I) complexes. 
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2.3. Copper(I) complexes: stability 
Apparent stability constants of the Cu(I)-peptide complexes were determined in the 
presence of the bathocuproine disulfonate (BCS) as a Cu(I)-binding competitor.[20] Because 
of the formation of several Cu(I)-peptide species, stabilities were calculated considering the 
formation of the CuP mononuclear complex, only to give an overall affinity of the peptides 
towards Cu(I) and hereby to allow a direct comparison between the peptides and to other 
values in the literature. The determined log�CuPpH7.  values presented in Table 5 show that all 
the peptides display high affinity for Cu(I) in the range of Cu(I) chaperone proteins, like 
Atx1.[11] Nevertheless, these values are close to each other, within the range of the 
experimental errors, indicating that the structural differences have no or little effect on the 
Cu(I) complex stabilities. 
Table 5. The apparent stability constants of the Cu(I)-peptide complexes at pH = 7.4. Experimental errors in 
the last digits are indicated in parenthesis. 
 � �������.� 
P3C 18.1(1) 
1C 17.3(3) 
1L 17.4(2) 
2C 17.8(4) 
2L 17.8(2) 
3C 17.9(4) 
2.4. Mercury(II) complexes: speciation 
Hg(II) is a metal ion with similar coordination properties to Cu(I) and therefore it is 
an often used probe of the oxygen and water sensitive Cu(I). To answer the question whether 
the complicated Cu(I) complexation behavior is originated from the peptide structure or it is 
specific for Cu(I) ion coordination, the interaction of the peptides with Hg(II) was also 
studied. Although, HgS3 coordination geometry naturally occurs, for example in Hg(II)-
bridged protein dimers, like those observed in the MerR metalloregulatory protein [147] or 
in the human copper chaperone Atox1,[17, 148] the formation of such a HgS3 coordination 
in model systems was rather challenging for a long time, because of the strong preference of 
Hg(II) for the linear coordination.[149-152] It was first successfully achieved by Pecoraro 
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et al. applying single oligopeptide chain three-helix bundles [153] and three-stranded coiled 
coils.[154] However, the third cysteine thiolate coordinated at relatively high pH with pKa 
of 8.6 and 7.6, respectively. 
The simple P3C compared to the three-stranded coiled coils is also able to stabilize 
the HgS3 environment and the speciation of the Hg(II) complexes is already published,[109] 
but the stabilities were not determined. 
In contrast to the RS−-Cu(I) UV LMCT bands, the LMCTs are good indicators of the 
coordination mode in the Hg(II)-thiolate systems. Bands characteristic for the HgS3 
environment are in the 240-320 nm wavelength range,[136, 155] while the di-thiolato Hg(II) 
complexes absorb only in higher energy region (< 230 nm).[74, 137, 138] Thus, the 
interaction between the peptides and Hg(II) was investigated by UV-vis spectroscopy. 
Stabilization of the absorbance was significantly faster than in case of Cu(I) complexation, 
which could be the result of a simpler speciation. Accordingly, continuous titration could be 
implemented by the addition of aliquots of Hg(II) solution from 0.0 to 3.0 equivalents at pH 
= 7.4. During the titration, intensive bands emerge on the UV spectra at λ = 240 and 280 nm 
with increasing Hg(II) concentration as presented by the Hg(II)-1C system in Figure 38. The 
linear increase of the absorbances up to 1.0 equivalent of Hg(II) reflects the formation of a 
mononuclear HgP complex. The position of these bands clearly shows that all the three 
cysteine moieties of the peptide participate in the coordination of the metal ion. The 
absorbance of the bands characteristic for the HgS3 geometry start to decrease beyond the 
1:1 ratio, however the band at ~ 230 nm stays intact. These phenomena can be attributed to 
the transformation of the mononuclear complex into polymetallic species where the Hg(II) 
ion is bound to two thiolates. 
 
Figure 38. UV titration of 1C with Hg(II) at pH = 7.4 (phosphate buffer, 20 mM). The insets show the 
evolution of the absorbances at λ = 240 and 280 nm as a function of the cHg(II)/cpeptide ratio. (cpeptide = 30 µM) 
72 
ESI-MS measurements support well the conclusions drawn by UV spectroscopic 
results. Only the mononuclear HgP complex can be observed on the spectrum recorded for 
the peptides with 1.0 equivalent of Hg(II) in the form of mono- ([P−H+Hg]+; m/z = 1152.3) 
and double charged ions ([P+Hg]2+, m/z = 576.8) (Figure 39). 
 
Figure 39. (+) ESI-MS spectra of 1C with 1.0, 1.5 and 2.0 equivalents of Hg(II) at pH = 6.9 (acetate buffer, 
20 mM) with the experimental and theoretical isotopic patterns of the detected species. Asterisks mark the 
sodium adduct of the corresponding species. (cpeptide = 100 μM) 
In the presence of 1.5 Hg(II) equivalents, the Hg3P2 is the major detected species in 
the forms of the [2P−ŐH+3Hg]2+ (m/z = 12ő0.8) and [2P−ŐH+3Hg+Na]3+ (m/z = 841.7) ions. 
This seems to correlate with the HgS2 coordination environment of the metal ion indicated 
by the observed changes of the UV spectra beyond the 1:1 Hg(II):peptide ratio (Figure 40). 
When 2.0 equivalents of Hg(II) are added, the Hg3P2 and Hg2P ([P−3H+2Hg]+, m/z = 1350.3) 
are detectable in similar amounts. This further transformation can be the explanation for the 
slight increase of the absorbance over 1.5 equivalents of Hg(II). 
 
Figure 40. Schematic representation of the Hg(II)-peptide complexes 
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2.5. The effect of pH on the Hg(II) complexation 
The effect of the pH on the Hg(II) complexion was also studied and the titration was 
followed by UV spectroscopy (Figure 41). The significant increase of the absorbance in the 
presence of 1.0 equivalent of Hg(II) compared to the free peptide at pH ~ 2.5 clearly shows 
that Hg(II) is already bound to the peptide even at this low pH. 
 
Figure 41. pH titration of 1C in the presence of 1.0 equivalent of Hg(II). The dashed line represents the 
spectrum of free 1C at pH = 2.5. The inset shows the evolution of the absorbances as a function of pH at 
280 nm. Symbols represent the experimental points and the line shows the fitted absorbances obtained by 
SpecFit. (cpeptide = 30 μM) 
Following the changes in the absorbance at 280 nm characteristic for the HgS3 
geometry shows that the increase of the pH results in a significant increase of the intensity 
corresponding to the transformation of the HgS2 species into the HgS3 in parallel with the 
deprotonation of the third cysteine thiol moiety. The absorbance at 280 nm is stable over a 
wide pH range (pH = 6-11). Spectroscopic data were satisfactorily fitted by considering one 
pKa value according to the following equation, where L represents the fully deprotonated 
form of the ligand. 
 HgLH ⇌ HgL + H p�a 
 HgS2 ⇌ HgS3 
The obtained pKa values of the Hg(II)-peptide complexes are presented in Table 6 
and follow the order of P3C < 3C ≈ 2C < 1C < 2L ≈ 1L. Although, these values are in a quite 
narrow range, some tendency can be observed which may be related to some kind of weak 
influences. The lowest pKa was determined for the peptide P3C, which indicates that the 
CxCxxC pattern of the coordinating Cys residues is probably more favorable for the 
formation of the HgS3 geometry than the CxCxC motif. The separation of the metal binding 
fragment from the turn motif may be the explanation of the slightly lower pKa of 2C and 3C 
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relative to that of 1C. The highest values of the two linear peptides may be the consequence 
of their larger flexibility and a more significant reorganization necessary for the coordination 
of the third Cys thiolate. 
Table 6. Deprotonation constants of the HgHL complexes. Experimental errors in the last digits are indicated 
in parenthesis. 
 ��������  
P3C 4.3(1)[109] 
1C 4.8(1) 
1L 5.1(1) 
2C 4.5(1) 
2L 5.0(1) 
3C 4.5(1) 
 
Interestingly, the values presented here are significantly lower than the pKa observed 
for the relevant Hg(II)-complex of a tris-cysteine functionalized tripodal pseudopeptide 
bearing amidated carboxyl groups[136] or of the Hg(II)-binding three-stranded coiled 
coils.[153] The bulkiness or the electron-withdrawing effect of the carboxyl function of the 
tripods probably has an unfavorable effect on the HgS2 ⇌ HgS3 transformation. In our 
peptides the thiol functions are more solvent-exposed, which are expected to deprotonate 
more easily than similar functions found in the hydrophobic pocket of triple coiled coils 
complexes. 
2.6. Stability of the Hg(II) complexes 
The high thiophilicity of Hg(II) makes the determination of the complex stabilities 
challenging, and as a solution for this problem, competitions with iodide ions were 
performed. Preliminary studies indicate that the iodide was not able to withdraw Hg(II) from 
the peptide complexes at pH = 7.4, therefore titrations were implemented under acidic 
condition at pH = 2.0. According to the pH dependent transformation of the HgP complexes, 
the stabilities determined at pH = 2.0 should correspond to the species with HgS2 geometry. 
As a first step, the molar absorption spectra of the Hg(II)-iodo complexes were determined 
by titrating the metal ion with I− under the same condition used in the competition 
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experiments and applying the recalculated stability constants of Hg(II)-iodo complexes 
presented in Table 2 (Figure 42). 
 
Figure 42. A) UV spectra recorded in the titration of Hg(II) with I− at pH = 2.0. The inset shows the 
evolution of the absorbance at 322 nm (•) and 280 nm (◦) as a function of the cI⁻/cHg(II) ratio. B) Molar 
absorption spectra of the Hg(II)-iodo complexes obtained in SpecFit. (cHg(II) = 30 μM, I = 0.1 M NaClO4) 
UV spectra recorded in the titration of the Hg1C complex with I− are presented in 
Figure 43. At the beginning of the titration, up to ca. 10 equivalents of I− no considerable 
spectral changes were observed. Further addition of I− resulted in the appearance of new 
bands characteristic for the [HgI3]
− and [HgI4]
2− complexes. Complete displacement of the 
peptide was achieved by the addition of ca. 2000 equivalents of I−. 
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Figure 43. UV spectra recorded in the titration of Hg1C with I− at pH = 2.0. The inset shows the evolution of 
the absorbance at 322 nm (•) and 280 nm (◦) as a function of the cI⁻/cHg(II) ratio. Symbols represent the 
experimental data, and solid lines represent the absorbances calculated by SpecFit. (cHg(II) = cpeptide = 30 μM) 
To obtain the apparent stability constants of the HgP complexes, the recorded series 
of spectra were fitted by SpecFit. The molar spectra and the stability of the Hg(II)-iodo 
complexes (Table 2) were fixed in the fitting procedure. Best fits were obtained when the 
formation of a HgPI ternary complex was also considered. The appearance of such species 
is probably a consequence of the flexibility of the peptide structures. These complexes are 
present only in the early stages of the titration in ~20% relative proportion. In case of HgP3C 
a somewhat larger fraction of HgPI could be observed. The formation of the mixed ligand 
complexes, according to the HgP + I ⇌ HgPI equation, is characterized by stabilities falling 
in the range of logK ~ 1.5-2.5. The determined apparent stability constants of the HgP 
complexes are presented in Table 7. These values are close to each other, indicating that all 
the six peptides have similar affinities for Hg(II) and that the differences in the peptide 
sequences do not notably affect the stabilities. Taken into account that at pH = 2.0 only two 
Cys thiolates are coordinated to the Hg(II), it is a possible explanation that the thiophilicity 
of Hg(II) easily governs the formation of the HgS2 structure, independently from the 
preorientations of the donor groups. 
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Table 7. Apparent stability constants and estimated stability data of the Hg(II) complexes. Experimental 
errors in the last digits are indicated in parenthesis. 
 � ������ .  � �������.�a � ������a � �����a 
P3C 27.2(1) 40.9 48.7 44.4 
1C 27.3(1) 40.5 48.8 44.0 
1L 27.1(1) 40.0 48.6 43.5 
2C 27.2(1) 40.7 48.7 44.2 
2L 27.0(1) 40.0 48.5 43.5 
3C 27.5(1) 41.0 49.0 44.5 
aApparent stability constants for pH 7.4 and formation constants of the HgHL and HgL species were estimated from the apparent 
stabilities obtained at pH = 2.0 
Formation constants were calculated for the protonated HgHL and the fully 
deprotonated HgL complexes from the relevant apparent stability constants applying the pKa 
values corresponding to the HgLH ⇌ HgL + H process (Table 6) and the proton dissociation 
constants of one of the peptides, 1L (p�aH L= 7.67(1), p�aH L= 8.56(1), p�aHL= 9.26(1))2 
according to the following train of thoughts: 
 The proton dissociation constants (�aHL, �aH L, �aH L) of the ligands can be expressed in 
the form of the overall formation constant of the fully protonated peptides (βH3L): [H L][L][H] = �H L = ���� ∙ ��� � ∙ ��� � (1) 
 The apparent stability of the mononuclear complexes at pH = 2.0 is defined as: �HgPpH . = [HgP][Hg][P] (2) 
 Since at pH = 2.0 Hg(II) binds to the monoprotonated ligand, the concentration of free 
peptide and the HgP complex can be estimated with the following concentrations: [HgP] ≈ [HgHL] (3) [P] ≈ [HL] (4) 
 Then equation 2 transforms into: �HgPpH . = [HgHL][Hg][H L] (5) 
                                                 
2 Acidic dissociation constants were determined by pH potentiometric titrations following a protocol describe 
earlier.[140] 
78 
 According to equation 1 [H3L] can be substituted by: [H L] = �H L[L][H]  (6) 
 and then rearrange equation 5 to �HgPpH . ∙ �H L ∙ [H] = [HgHL][Hg][L][H] (7) 
 This is not else than the formation constant of HgHL complex: �HgHL = [HgHL][Hg][L][H] (8) 
 The combination of (7) and (8) leads to an expression allowing the calculation of 
βHgHL from the experimentally measured stability data: �HgHL = �HgPpH . ∙ �H L[H]  (9) log�HgHL = log�HgPpH . + log�H L − pH (10) 
 Formation constants for the parent HgL complexes can be obtained by using the 
spectrophotometrically determined deprotonation constants (p�aHgHL) for the HgHL ⇌ 
HgL+ H process: log�HgL = log�HgHL − p�aHgHL (11) 
The calculated thermodynamic stability constants (logβHgHL and logβHgL) are also 
presented in Table 7. These data also fall in a narrow range, confirming that the orientation 
of the Cys-sidechains has only a weak influence on the complex stabilities. Nevertheless, 
the slightly lower affinity of the linear peptides suggests the need for a more pronounced 
structure of the peptide backbone provided by the cyclization. 
The thermodynamic stability constants of the HgL species of our peptides allow the 
comparison with Hg(II)-bisthiolate complexes of highly constrained bis-thiol ligands. Our 
peptides, indeed, display very similar Hg(II)-binding affinities to that of the well-known soft 
metal ion chelator BAL (logβHgL = 44.8)[156] which forms a highly stable 5-membered 
chelate ring around the metal ion. Comparison of our data to the stability of the HgL species 
of the tetrapeptide Ac-Cys-DPro-Pro-Cys-NH2 (logβHgL = 40.0)[137] clearly indicates that 
the structure of our peptides are prone to easily rearrange to a suitable form for the tridentate 
coordination of Hg(II) and thus the larger number of Hg(II)-thiolate bonds is revealed in 
higher affinities. 
Apparent stabilities of the HgP mono-complexes can be re-calculated for any desired 
pH values from the calculated thermodynamic stability constants (Table 7) allowing a direct 
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comparison of the Cu(I)- and Hg(II)-binding affinities of the studied peptides. The peptides 
show 20 orders of magnitude larger affinity for Hg(II) (logβHgPpH7.4 ~ 41) than for Cu(I) 
(logβHgPpH7.4 ~ 18) at physiological pH, due to the significantly softer character of Hg(II). 
 
The three-cysteine containing peptides are found to be too flexible to control the 
Cu(I) complex speciation leading to the formation of several polymetallic species, but they 
are well adapted to accommodate one Hg(II) ion in a tri-thiolate environment. This 
significant difference between the behavior of the peptides towards Cu(I) and Hg(II) also 
indicate that the use of Hg(II) as a probe for Cu(I) coordination with sulfur-rich peptides or 
proteins in physiological conditions is not always fully appropriate. 
  
IN SUMMARY 
 different complex speciation of the peptides with Cu(I) and Hg(II) 
 complicated Cu(I) complex speciation 
 the peptide structure is too flexible to control the Cu(I) speciation 
 affinity for Cu(I) is in the range of 1017-1018 
 simple Hg(II) complex speciation: mononuclear complex with HgS3 geometry at 
physiological pH 
 pH dependent HgS2 ⇌ HgS3 transformation, with relatively low pKa 
 large Hg(II) complex stability (logβHgPpH7.4 ~ 41) 
 sequences are adapted for trithiolate Hg(II) coordination 
 Hg(II) is not always an appropriate Cu(I) probe 
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3. Efficient Cu(I) binding of a rigid tetrapeptide incorporating two cysteines linked 
by a β turn 
3.1. Rational peptide design to control the metal binding 
Studies of the series of the relatively long 3-cysteine-containing peptides 
demonstrated that Cu(I) complexation with quite flexible peptides could be complicated. 
Therefore, rational ligand design can be a logical solution to control the speciation of Cu(I) 
complexes. Introducing amino acids that induce β turns is one of the options to rigidify 
peptide scaffolds and enhance metal binding affinity.[157] β turn is the simplest defined loop 
structure with conformational characteristics.[158] It consists of four amino acid residues 
(from i to i+3) and defined by a hydrogen bond between the C=O of the residues i and the 
NH of the i+3. There are four types of beta turns depending on the Φ and Ψ torsion angles 
of residues i+1 and i+2. These torsion angles are the following Φi+1 = −60, Ψi+1 = −30, Φi+2 
= −90 and Ψi+2 = 0 in type I, and Φi+1 = −60, Ψi+1 = 120, Φi+2 = 80 and Ψi+2 = 0 in type II. 
Type I’ and II’ are the mirror images of type I and II.[159, 160] 
The cyclic proline (Pro) is the most constrained natural amino acid, which can induce 
a turn. As it was presented in the Literature review, simple Cu(I) complex speciation was 
achieved with cyclic peptides encompassing β turn inducer xPGx motifs by the Delangle 
group.[74, 100] Similarly, it was demonstrated that β sheet like peptide scaffold was a key 
element in achieving high affinity for uranyl cation.[161] Mononuclear UO2
2+ complexes of 
constrained structured peptides with two PG motifs had significantly higher stability than 
complexes formed with the more flexible ones containing only one turn, while the 
completely unstructured linear peptide formed nondefined polymetallic species of low 
affinity. Iranzo and co-workers proved that cyclization had a remarkable effect on the Cu2+ 
coordination properties of decapeptides bearing two prolylglycine units. The cyclic peptides 
had a higher affinity for Cu2+ than the linear ones at all studied pH values. Difference in Cu2+ 
exchange rate was also observed between the two structures.[162, 163] 
Some amino acids of D configuration were also shown to stabilize peptide 
structures.[158, 164-166] Iranzo’s team also demonstrated that the introduction of the DPro-
Pro motif into a short peptide sequence was very favorable for heavy metal chelation.[137] 
The tetrapeptide Ac-Cys-DPro-Pro-Cys-NH2 (CDPPC) incorporating two cysteines at the 
two termini was designed to mimic the CxxC consensus sequence found in 
metallochaperones or metal transporters.[167-169] This peptide forms a mononuclear 
Hg(II)-complex with a large stability (logK = 40.0). The favorable effect of the DPro-Pro 
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motif on Hg(II) coordination was proven by comparison to the CPPC peptide incorporating 
two natural proline residues. A three orders of magnitude lower stability constant was 
estimated for the dithiolatomercury(II) complex of CPPC underscoring the significance of 
the preorganized DPro-Pro containing sequence. 
The outstanding Hg(II)-sequestering features of CDPPC suggest that this short 
sequence may also be interesting in view of chelating Cu(I), a soft metal ion with 
coordination preferences resembling those of Hg(II). We also studied the behavior of a less 
rigid structure introduced by the more flexible Xxx-Pro-Gly-Xxx motif in the peptide Ac-
Cys-Pro-Gly-Cys-NH2 (CPGC). The schematic structures of the peptides are presented in 
Figure 44. 
 
Figure 44. Schematic structures of the tetrapeptides with β turn inducing motifs. The dashed line symbolizes 
the H-bond in the turn present in CDPPC 
3.2. Characterization of the apopeptides 
The solution structures of the peptides were investigated by 1H NMR. Complete 
assignment of the proton resonances (Table 8) was achieved by the combination of 1D 
(Figure 45) and 2D (COSY, TOCSY, NOESY) methods. The 1H NMR spectrum of CDPPC 
recorded at 298 K in water reflects the presence of peptides with different structures. The 
major conformation represents 73% of the total peptide concentration. The resonances 
attributed to the minor components disappear upon Cu(I) addition (discussed later), which 
suggests that the corresponding minor species are in a relatively slow exchange with the 
major one at the NMR timescale and that Cu(I) restricts the peptide into one specific 
conformation in the complex. 
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Figure 45. 1H NMR spectra of the free peptides in phosphate buffer in D2O (20mM, pD = 7.4). 
(cpeptide ~ 1.00-2.00 mM) 
Table 8. Assignments of the 1H NMR resonances ( , ppm) of the free peptides (major conformation) in 
phosphate buffer (20 mM, pD = 7.4, D2O). Amide protons were identified in H2O/D2O, 9/1, v/v. 
CPGC NH CαH CβH Others 
Cys1 8.28 4.67 2.82 (Ac) 1.97 
Pro2 − 4.38 1.93; 2.26 ( ) 2.00 ( ) 3.70; 3.78 
Gly3 8.46 3.93 −  
Cys4 8.09 4.47 2.88 (NH2) 7.14; 7.63 
 
CDPPC NH CαH CβH Others 
Cys1 8.21 4.77 2.77 (Ac) 1.95 
DPro2 − 4.41 2.01; 2.23 ( ) 2.02 ( ) 3.64; 3.89 
Pro3 − 4.64 1.86; 2.28 
( ) 2.03  
( ) 3.7Ő 
Cys4 7.87 4.32 2.87; 3.02 (NH2) 7.07; 7.14 
 
Since β turns are characterized by a hydrogen bond between the C=Oi and NH(i+3) 
groups, the temperature coefficients of the amide proton resonances were measured since 
they are good indication of the presence or absence of H-bonds. Weaker intermolecular 
hydrogen bonds formed with the solvent molecules are more easily cleaved with increasing 
temperature, therefore the chemical shifts of solvent exposed NH display higher temperature 
dependence. On the other hand, it is generally assumed that NH resonances owing 
temperature gradient less negative than −Ő.ő ppb/K are solvent-shielded and participate in 
strong intramolecular hydrogen bonds providing a constrained peptide structure.[170-174] 
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Table 9 compares the measured temperature coefficients of the Cys amide proton resonances 
in the two peptides. These values show that the NH of the Cys4 residue is significantly more 
solvent shielded than that of the Cys1 in both cases. 
Table 9. Temperature coefficients of the amide proton resonances of the Cys residues 
 Δ /ΔT (ppb/K) 
 CDPPC CPGC 
 Cys1 Cys4 Cys1 Cys4 
Free L −9.3 –4.0 –8.2 –6.3 
Cu4L3 –6.7 –2.5   
 
The temperature coefficient determined for the NH resonance of the Cys4 residue in 
CDPPC (−Ő.0 ppb/K) strongly supports the hydrogen bond between the C=O of Cys1 and 
the NH of Cys4 characteristic for a  turn. This value in CPGC is significantly smaller 
(Δ /ΔT = −6.3 ppb/K) indicating the absence of such a H-bond as a consequence of the less 
structured backbone. 
3.3. Copper(I) ion complexes of CDPPC: spectroscopic results 
The interaction between CDPPC and Cu(I) was investigated by UV-vis spectroscopy 
(Figure 46). The appearance of the characteristic RS− to Cu(I) LMCT transition at 263 nm 
[133] in parallel with increasing Cu(I) concentration proves the coordination of the cysteine 
thiolates to Cu(I). The absorbance at this wavelength increases linearly up to 1.3 equivalents 
of Cu(I) with a molar absorbance value consistent with the previous results (  ~ 7000 
M−1cm−1). 
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Figure 46. UV titration of CDPPC with Cu(I) at pH = 7.4 (phosphate buffer, 20 mM). The inset shows the 
evolution of absorbance as a function of the cCu(I)/cCDPPC ratio. (cpeptide = 30 µM) 
Intense bands appear in the LMCT region on the recorded CD spectra as a result of 
Cu(I) addition, characterized with extrema at λ = 237 (+), 2ő6 (+), 2λ0 (−) and 3Ő0 (+) nm 
(Figure 47). Similarly to UV spectroscopic observations, the intensity of these bands 
increase linearly with increasing Cu(I) concentration until a sharp breakpoint at 1.3 Cu(I) 
equivalents. The two isodichroic points were observed at λ = 277 and 321 nm demonstrating 
the transformation of the free peptide into a single Cu(I) complex before the breakpoint. 
 
Figure 47. CD titration of CDPPC with Cu(I) from 0.0 to 1.3 equivalents at pH = 7.4 (phosphate buffer, 
20 mM). The inset shows the evolution of the molar ellipticity at  = 256 and 290 nm as a function of the 
cCu(I)/cCDPPC ratio. (cpeptide = 30 µM) 
During the 1H NMR titration of CDPPC with Cu(I) the signals of the free peptide 
gradually transformed to new, narrow signals and completely disappeared by the addition of 
1.33 equivalents of Cu(I) as presented in Figure 48. The well-resolved signals support the 
formation of a unique species. The proton resonances in the Cu(I)-peptide complex 
(highlighted in green in Figure 48) were assigned by TOCSY and ROESY experiments 
(Table 10). 
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Figure 48. 1H NMR spectra of the aliphatic region of CDPPC  with increasing amounts of Cu(I) in phosphate 
buffer in D2O (20 mM, pD = 7.4,). (cpeptide = 1.58 mM) 
Table 10. Assignments of the 1H NMR resonances ( , ppm) of Cu4(CDPPC) in phosphate buffer (20 mM, 
pD = 7.4, D2O) at 298 K, 500 MHz. Amide protons were identified in H2O/D2O, 9/1, v/v. 
Cu4(CDPPC)3 NH CαH CβH Others 
Cys1 7.81 4.74 3.12; 3.44 (Ac) 2.02 
DPro2 − 4.54 2.04; 2.11 ( ) 1.8ő ( ) 3.62 
Pro3 − 5.08 2.18; 2.50 ( ) 1.87; 2.02 ( ) 3.ő2; 3.61 
Cys4 9.24 4.10 2.54; 3.10 (NH2) 6.96; 7.45 
 
As it was seen earlier UV-data alone does not provide information about the 
speciation. However, the three spectroscopic results together, where the endpoint of the 
titration was observed at 1.33 equivalents of Cu(I), indicate the formation of a Cu:peptide 
complex of a 1.33:1.00 stoichiometry. This may be reminiscent of a Cu4S6 cluster in a 
Cu4(Peptide)3 complex. 
In all the three cases the continuation of the titrations shows the transformation of 
this assumed cluster into other species in the presence of more than 1.33 Cu(I) equivalents. 
Further evolution of the LMCT bands in UV and CD titrations was observed until 2.5 
equivalents of Cu(I). The 1H NMR resonances become broad indicating the formation of 
more than one species. These species formed with an excess of Cu(I) are likely to be Cu(I)-
thiolate clusters too, with higher nuclearity. 
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Further analysis of the NMR spectra of the Cu4P3 complex reveal that the 
coordination of the Cu(I) ion mainly affect the signals of the cysteine residues. The CαH 
resonances of the Cu(I) complex are systematically upfield shifted compared to the free 
peptide. The CβH2 resonances are shifted downfield in Cys1 and upfield in Cys4. These 
protons are detected as an ABX systems, with a significant difference between the chemical 
shifts of the two protons belonging to the same carbon atom [AB = 0.32 and 0.56 ppm for 
the CβH2 protons of Cys1 and Cys4, respectively]. This is an indication of a significantly 
different chemical environment and therefore a well-ordered and rigid structure of the Cu(I)-
thiolate cluster. 
The temperature coefficients of the amide proton resonances were also measured in 
the complex. The −2.ő ppb/K value determined for the NH of Cys4 shows that this signal 
is less affected by the temperature compared to the free ligand (see Table 9). This indicates 
the H-bond between the amide oxygen of the first Cys residue and the amide proton of the 
fourth Cys is stronger in the complex and it provides a tighter structure. 
3.4. Copper(I) ion complexes of CDPPC: molecularity 
ESI-MS spectra were acquired to confirm the composition of the Cu(I)-CDPPC 
complex. Samples containing the peptide and 0.9, 1.33 and 2.0 equivalents of Cu(I) were 
analyzed. In the first two samples the same species were detected with different relative 
abundance. The spectrum of the sample containing 1.33 Cu(I) equivalents reflects the 
presence of three complexes (Figure 49). The Cu4P3 is the major detected species in the form 
of the [3P−6H+4Cu]2– ion (m/z = 812.3). The two other observed species are the Cu3P2 
([P−4H+3Cu]–; m/z = 1104.8) and CuL ([P−2H+Cu]–; m/z = 520.1). A tandem MS/MS 
experiment on the ion of m/z = 812.3 proves that these two other species are produced by 
fragmentation. This confirms the formation of a single Cu4P3 complex when the 
Cu(I)/peptide ratio is below 1.33. The characteristic peaks of the [3P−6H+4Cu]2– ion do not 
appear in the ESI-MS spectrum of the sample containing 2.0 equivalents of Cu(I). Although 
the quality of the recorded spectrum is relatively poor with low signal intensities, the 
formation of several polymetallic species including Cu4P2, Cu5P2, Cu9P5 or Cu7P3 can be 
evidenced. 
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Figure 49. Top. (−)ESI-MS spectrum of CDPPC  in NH4AcO buffer (20 mM, pH = 6.9) in the presence of 
1.33 equiv. Cu(I). (cpeptide = 100 μM) Down. Fragmentation of the [3P−6H+4Cu]2–  ion at m/z = 812.3. Insets 
give the comparison of the experimental and theoretical isotopic patterns of the detected species. * indicates 
the oxidized peptide 
ESI-MS experiments provide information about the metal complex speciation only 
under specific experimental conditions in gas phase, which is only indicative of species 
found in solution. Nevertheless, the well-resolved 1H NMR spectrum of the Cu(I)-CDPPC 
complex made it possible to measure the diffusion coefficient (D) by pulse gradient spin 
echo (PGSE) NMR to gain deeper insights about the molecularity of the species in solution. 
According to the Einstein-Stokes equation, the diffusion coefficient (D) is related to the rH 
hydrodynamic radius (also called as Stokes radius) of the molecule considered as a hard 
sphere. � = �6���� 
where k is the Boltzmann’s constant, T is the absolute temperature and  is the viscosity. As 
the Stokes radius is related to the cube root of the molecular weight (rH ~√�), the molecular 
weight (Mi) of the species under interest can be deduced from the ratio of its experimental 
diffusion coefficient (Di) and that of a closely-related reference molecule (Dr) with a known 
molecular weight (Mr).[113] 
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���� = √����  
For a sample containing CDPPC and 1.33 equivalents of Cu(I) Di = 1.λő∙10−9 m2/s 
diffusion coefficient was determined in phosphate buffer in D2O containing 7.9 % CD3CN 
in volume originated from the solvent of the Cu(I) solution. The free peptide, as a molecule 
with known molecular weight (M = 459 g/mol), was used as a reference. Its diffusion 
coefficient (Dr = 2.λλ∙10−10 m2/s) was measured in the same solvent mixture to provide the 
same viscosity. From these data, a molecular mass Mi = 1645 g/mol was calculated for the 
Cu(I) complex, which is in a very good agreement with the theoretical molecular weight of 
the [Cu4P3H-6]
2- cluster (M = 1625 g/mol). These data are in total accordance with other 
spectroscopic studies and point to the exclusive formation of the Cu4P3 cluster with the 
constrained peptide CDPPC for Cu(I)/P ratios lower than 1.33. 
Among proteins that participate in copper homeostasis many form the same Cu4S6 
type cluster. Such a cluster can be found, among others, in the cytosolic C-terminal domain 
of the Ctr1 copper transporter,[11] the fully reduced form of the Cox17 chaperone of 
cytochrome c oxidase,[12, 13, 175] the metal-responsive transcription factor of Drosophila 
[176] or the transcription factor Amt1.[177] Interestingly, the simple CDPPC peptide can 
mimic the behavior of these proteins and forms the cluster in a so-called all-or-nothing, 
cooperative manner under physiologically relevant condition. 
It is also worthy to note, that the two soft metal ions, Cu(I) and Hg(II), interact 
differently with CDPPC. Hg(II) was observed to form mononuclear complex with a linear 
coordination geometry, whereas the exclusive formation of the Cu4P3 species incorporating 
trigonally coordinated metal ions was proved for Cu(I). This supports our conclusion in the 
previous chapter that the analogy between these two metal ions has to be handled with 
extreme care. 
3.5. Copper(I) ion complexes of CPGC: spectroscopic results 
The Cu(I) binding of the less rigid CPGC peptide was also analyzed by means of 
UV-vis, CD and NMR spectroscopy and ESI-MS. The complex formation turned out to be 
more complicated compared to CDPPC. Although the UV titration shows the linear increase 
of the RS− to Cu(I) LMCT band centered at 236 nm up to ca. 1.5 Cu(I) equivalents (Figure 
50), the evolution of the CD features is rather characteristic for the formation of several 
species (Figure 51). ESI-MS spectra are of rather poor quality with low signal intensities 
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regardless of the applied Cu(I)/P ratio, as often observed with thiolate ligands forming a 
mixture of Cu(I) species. The broad signals in the 1H NMR spectra, observed after Cu(I) 
addition, may be due to an equilibrium between several species coexisting in an intermediate 
exchange rate at the NMR timescale. Therefore, in agreement with other spectroscopic 
results, the formation of a mixture of several species is highly probable with this more 
flexible compound. 
These results unambiguously reveal the importance of the rigid, pre-organized 
structure of CDPPC peptide in controlling the speciation of Cu(I) complexes in water at 
pH = 7.4. 
 
Figure 50. UV titration of CPGC with Cu(I) at pH = 7.4 (phosphate buffer, 20 mM). The inset shows the 
evolution of the absorbance at  = 263 nm as a function of the cCu(I)/cCPGC ratio. (cpeptide = 30 µM) 
 
Figure 51. CD titration of CPGC with Cu(I) at pH = 7.4 (phosphate buffer, 20 mM). (cpeptide = 30 µM) 
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Figure 52. 1H NMR spectra of the aliphatic region of CPGC with increasing amounts of Cu(I) in phosphate 
buffer in D2O (20 mM, pD = 7.4). (cpeptide = 1.91 mM) 
3.6. The stability of the copper(I) complexes 
Apparent stability constants of the Cu(I) complexes of CDPPC and CPGC peptides 
at pH = 7.4 were also determined in the presence of the competitor BCS. However, when 
the samples were prepared in the regular way (CuP + BCS), the equilibration time was too 
long (weeks) in the case of CDPPC. Therefore, we decided to change the mixing order of the 
components and attempted to withdraw the Cu(I) from [Cu(BCS)2]
3− complex with the 
peptides. The stabilization was still slower in the system of CDPPC than with CPGC. This 
explains the fewer points recorded in the former system (Figure 53). The different 
equilibration times might reflect the different structures of the complexes formed with the 
two peptides. 
 
Figure 53. Absorbance at  = 483 nm recorded during the titration of Cu(BCS)2  with CDPPC (○) and CPGC 
(□) at pH = 7.Ő (phosphate buffer, 20 mM). The solid lines represent the absorbances calculated by SpecFit. 
(cCu(I) = 30 µM; cBCS = 300 µM) 
Figure 53 clearly presents the striking difference between the affinities of the two 
peptides for Cu(I). 15 equivalents of CDPPC relative to Cu(I) displace all the metal ion from 
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the BCS complex leading to the total loss of absorbance at λ = 483 nm. In contrast, 45 
equivalents of CPGC (not shown) were not enough for a complete displacement. The UV-
vis spectra recorded during the titration with CDPPC were satisfactorily fitted by considering 
only the Cu4P3 cluster and logβ43pH7.4 = 78.9 was determined. The complicated speciation of 
the Cu(I)-CPGC complexes prevented a fully appropriate fitting. Therefore, apparent affinity 
constants were calculated considering the formation of the 1:1 mononuclear complex for 
both peptides to allow a direct comparison. Data shown in Table 11 display a one order of 
magnitude difference in favor of CDPPC giving a further advantage of the preorganized 
peptide backbone. CDPPC not only mimics the structural features of some Cu proteins, but 
its affinity for Cu(I) is also in the range of previously reported stabilities of proteins involved 
in Cu homeostasis.[11] 
Table 11. Apparent stability constants of the Cu(I) and Zn(II) complexes of CDPPC and CPGC at pH = 7.4 
 CDPPC CPGC 
 Cu(I) Zn(II) Cu(I) Zn(II) 
logβ11pH 7.4 17.5(1) 6.3(1)a 16.4(1) 5.6(1)a 
  6.4(1)b  7.4(2)b 
logβ12pH 7.4    13.1(2)b 
logβ43pH 7.4 78.9(3)   
aCalculated from competition experiments with zincon. 
bCalculated from UV titrations with Zn(II). 
3.7. Zinc(II) complexes: spectroscopy and stability 
Zinc(II), as an abundant metal ion in cells, is a potential competitor in Cu(I) binding. 
Therefore, the Zn(II) complexation of CDPPC and CPGC was also studied by UV titrations 
and ESI-MS experiments. The addition of Zn(II) aliquots to the solution of the lignads results 
in the increase of absorbance in the wavelength range characteristic for the RS− to Zn(II) 
LMCT (λ < 240 nm).[178, 179] The CDPPC reacts with Zn(II) in a quite simple manner and 
the absorbance reaches the maximum around 1.0 equivalent of Zn(II) added. The recorded 
ESI-MS spectra showed the formation of only the mononuclear complex (Figure 55). ZnP2 
can be detected only under ligand excess condition, but in negligible amount. In contrast, 
the increase of absorbance has a breakpoint at 0.5 equivalent of Zn(II) during the titration of 
CPGC indicating the formation of ZnP2 complex where the metal ion is coordinated by four 
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thiolate donor groups. The further evolution of absorbance at 240 nm probably reflects the 
transformation of ZnP2 to ZnP. Accordingly, ESI-MS shows the significant contribution of 
ZnP2 besides the ZnP complex both in the presence of 0.5 and 1.0 equivalent of Zn(II). 
 
Figure 54. UV titration of CDPPC (A) and CPGC (B) with Zn(II) at pH = 7.4 (phosphate buffer, 20 mM). 
The insets show the evolution of the absorbance at chosen wavelengths as a function of the cZn(II)/cpeptide ratio. 
(cpeptide ~ 30 μM) 
 
Figure 55. (−)ESI-MS spectra of CDPPC and CPGC  with 1.0 equivalent of Zn(II) at pH = 6.9 (NH4AcO 
buffer, 20 mM) with the experimental and theoretical isotopic patterns of the detected species. 
(cpeptide = 100 μM) 
Apparent stability constants of the ZnP complexes were determined by two different 
methods. UV titrations of the peptides with Zn(II) were fitted by considering the formation 
of only the ZnP complex in the sample of CDPPC and the ZnP and ZnP2 with CPGC. The 
results reported in Table 11 show significantly lower Zn(II)-binding affinity compared to 
Cu(I). Competition studies with zincon, a well-known Zn(II) chelator,[123] confirm 
affinities in the same range. The good agreement between the two independent determination 
in case of CDPPC confirms the simple speciation with the formation of the ZnP complex. 
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IN SUMMARY 
 DPro-Pro motif induces more rigid backbone than Pro-Gly 
 CDPPC forms a Cu4P3 cluster involving a Cu4S6 core with high stability 
 CDPPC mimics the cluster formation and stability of natural Cu(I) proteins under 
physiological conditions 
 CPGC forms several Cu(I) species with lower stability 
 Pre-organization of the metal binding groups is essential for the control of Cu(I) 
complex speciation 
 Both peptides display large selectivity for Cu(I) vs. Zn(II) 
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SUMMARY 
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VI. Summary 
The essential micronutrient copper participates in several biological processes, like 
respiration, iron homeostasis, antioxidant defense or pigment formation. However, excess of 
copper can promote ROS formation and thus induce oxidative damages. Therefore, 
intracellular copper concentration is under strict control. Menkes and Wilson’s diseases are 
genetic disorders causing impairment in copper homeostasis leading to copper deficiency or 
overload, respectively. Wilson’s disease is treated by chelation therapy, but the presently 
used drugs have several adverse side effects. New peptide or tripodal pseudopeptide ligands 
that display high affinity for the intracellular Cu(I) and target hepatic cells have been 
developed by Delangle et al. Some of them are currently proposed as highly specific drugs 
for localized copper chelation therapy in Wilson’s disease. 
My Ph.D. work consisted of the design of three groups of cysteine containing 
peptides and the characterization of their Cu(I) complexes to determine whether they are 
appropriate candidates for the treatment of Wilson’s disease. The interaction of some 
peptides with Hg(II), which is a metal ion possessing similar coordination properties to Cu(I) 
and therefore an often used probe of the oxygen and water sensitive Cu(I), or with the 
ubiquitous Zn(II), which is a potential intracellular competitor, was also studied. 
The peptides were designed following three different approaches. In a first strategy, 
we attempted to take advantage of the outstanding selectivity and sensitivity of the bacterial 
copper efflux regulator protein CueR by studying oligopeptides based on the metal binding 
motif of CueR involving two cysteine residues. Second, three-cysteine containing linear and 
cyclic peptides were designed with the aim of merging the better internalization of peptides 
by hepatocytes and the high Cu(I) affinity of tripods previously studied in the Delangle’s 
lab. Finally, the advantages of a highly preorganized peptide structure were exploited in a 
short, rigid tetrapeptide where two cysteines were linked by a turn motif (CDPPC). For 
comparative purposes studies were also performed with another, less rigid tetrapeptide 
ligand containing the PG unit as a turn inducing motif 
Terminally protected linear peptides were synthesized by solid phase peptide 
synthesis following the Fmoc protocol. For the cyclic peptides, linear precursors with 
unprotected termini were assembled by the same method. After the cleavage off the resin, 
cyclization was performed. The crude products were purified by reversed phase HPLC. The 
purity was checked by analytical HPLC and ESI-MS. 
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Since the cysteine moieties and Cu(I) are sensitive for oxidation, all sample 
manipulations were performed in a glovebox under argon atmosphere. The majority of the 
experiments were carried out at pH = 7.4 in buffered media. In a few cases, pH titrations 
were also executed at constant metal-to-ligand concentration ratios. The interaction of the 
peptides with the metal ion was studied by UV-vis, CD and NMR spectroscopy and ESI-
MS. The stability of the peptide-metal ion complexes was determined by competition 
reaction with well-known ligands. 
The three CueR model peptides, EC, VC and HS display very similar behavior 
towards Cu(I). Mononuclear complexes are formed in excess of the ligands and they 
transform into polynuclear species in the presence of Cu(I) excess. Based on the observed 
thiolate to Cu(I) charge transfer transitions in the UV and CD spectra, Cu(I) is bound by the 
two cysteine residues. For HS, 1H NMR spectra show the involvement of the histidine 
residue in metal ion coordination. Analysis of a series of pH dependent UV spectra reveals 
that the complex formation is complete above pH = 7.0 and decrease of pH induces the 
decoordination of cysteines in two steps leading to the complete loss of LMCT absorbances. 
The pKa values belonging to these processes are significantly below the physiological pH 
indicating that they are probably not relevant in biological Cu(I) sequestration. 
The stabilities of the mononuclear complexes at pH = 7.4 determined in the presence 
of the competitor ligand BCA are quite large (logβ11pH7.4 ~ 16) and similar to those obtained 
for peptides incorporating the CxxC or the CxxxxC motif. This result shows that the length 
of the spacer between the Cys residues affects little the affinity towards Cu(I). Therefore, 
the driving force for the coordination of the soft Cu(I) cation is expected to be mainly the 
formation of the two strong bonds with the soft thiolate donors. Comparison of stability 
constants with previous results shows that the peptides are highly selective for Cu(I) against 
Zn(II), but have similar affinity for Ag(I). Although, the Cu(I)-binding affinities of these 
peptide models are 5–6 orders of magnitude lower than that of the native CueR protein, they 
still resemble the ability of the protein to exclusively accommodate one metal ion under 
ligand excess conditions. This, combined with the large affinity and high selectivity vs. 
Zn(II), are the features that are advantageous in the view of the development of new Cu(I) 
chelators. 
In the three-cysteine-containing cyclic peptides P3C, 1C, 2C and 3C and their linear 
derivatives 1L and 2L, the Cys residues are arranged in CxCxxC or CxCxC motifs, found in 
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metallothioneins. With this series, the effects of different structural influencing 
modifications on the metal ion binding were also studied. 
The Cu(I) complex formation of all the six peptides was found to be rather 
complicated. This was first indicated by UV-vis studies when the LMCT absorbances 
stabilized only after 2 hours of equilibration during the titration of the peptides with Cu(I). 
Therefore, the use of independently prepared samples was necessary. Although, the UV 
titrations reveal a seemingly simple evolution of absorbances with an endpoint that refers to 
the formation of polymetallic species of an overall (Cu2P)n stoichiometry, the recorded CD 
spectra and ESI-MS experiments evidence the presence of a mixture of polymetallic species. 
Consequently, the peptides proved to be too flexible to control the speciation and hereby 
leading to the formation of several species. 
Because of the undefined speciation, the average affinity of the peptides for Cu(I) at 
pH = 7.4 was determined. Therefore, the UV spectroscopic results of the competition with 
BCS were evaluated by considering the formation of only the mononuclear CuP complex. 
All peptides display high affinity towards Cu(I) in the range typical of Cu(I) chaperone 
proteins. The similar logβ11pH7.4 ~ 18 values indicate that the structural differences have 
minor effect on the stability of the Cu(I) complexes. 
To reveal whether this complicated behavior is originated from the peptide structure 
or it is specific for Cu(I), the interaction with Hg(II), a soft metal ion possessing similar 
chemical properties, was also studied. Mononuclear HgP complexes are formed when the 
ligands are in excess and the complex formation is significantly faster compared to Cu(I). 
The position of the thiolate to Hg(II) LMCT at λ = 280 and 240 nm clearly demonstrates that 
Hg(II) is coordinated by all the three Cys residues of the peptides at pH = 7.4. In the presence 
of Hg(II) excess, the mononuclear complexes transform into polymetallic species adopting 
the more favorable HgS2 coordination mode. The results of the UV titrations and MS 
experiments strongly support the formation of Hg2P3 complexes up to 1.5 equivalents of 
Hg(II), that transform into other species with an increasing metal ion excess. 
UV-pH titrations showed an HgS2 ⇌ HgS3 transformation with pKa = 4.3-5.1 values 
characterizing the deprotonation of the third cysteine thiol. These values are relatively close 
to each other for the six peptides, indicating that the structural differences affect little the 
stability of the HgS3 species. However, the observed tendency reveal that the CxCxxC motif 
in P3C is more favorable, just like the longer distance from the turn motif in 2C and 3C 
compared to 1C, and the cyclic against the linear structure. Interestingly, these pKa values 
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are significantly lower than those obtained for the three-stranded coiled coils, which is 
probably related to the very different water-accessibility of the thiol groups. 
The apparent stability of the HgP complexes was determined at pH = 2.0 by 
competition with I− ions. All peptides display rather similar affinities for Hg(II) showing that 
the preorientation of the donor groups has only a modest influence on the stabilities and the 
high thiophilicity of Hg(II) easily governs the formation of the favored HgS2 structures. The 
apparent stability constants estimated for pH = 7.4 show a more than 20 orders of magnitude 
larger affinity of the peptides for Hg(II) than for Cu(I) due to the significantly larger 
thiophilicity of Hg(II). Stabilities of the HgP complexes are of the same magnitude as the 
Hg(II) complex of the well-known heavy metal chelator BAL, which forms a highly stable 
five member chelate ring by the coordination of two thiolate groups. Our peptides display 
higher affinity for Hg(II) than the highly constrained CDPPC peptide as a consequence of 
the higher number of coordinating donor groups. The large stability constants together with 
the low pKa values clearly indicate that all these three-cysteine-containing peptides are 
adapted for an efficient trithiolate coordination of the thiophilic cation Hg(II). 
The striking difference in the behavior of the peptides towards the two soft metal ions 
demonstrate that the use of Hg(II) as a probe for Cu(I) coordination with sulfur-rich peptides 
or proteins in physiological conditions may not always be fully appropriate. 
The effect of the preorganization on the metal binding properties was studied on two 
tetrapeptides where two cysteines were linked by a β turn inducer motif, the DPro-Pro 
(CDPPC) or Pro-Gly (CPGC). CDPPC was confirmed to possess a more rigid structure by 
measuring the 1H NMR temperature coefficient of the amide proton of the Cys4 residue that 
indicates the presence of a hydrogen bond between the C=O group of Cys1 and NH of Cys4. 
The UV, CD and NMR titration reveal that CDPPC form a single Cu(I) complex until 1.33 
equivalents of Cu(I) and the results of DOSY NMR and ESI-MS experiments prove that this 
species is a Cu4P3 cluster with a Cu4S6 core where a Cu(I) ion is in a highly favorable 
trithiolate coordination. It is worthy to note, that this simple peptide is able to mimic the 
cluster formation that are typical in proteins like Ctr1 or Cox17. In contrast, all experimental 
data refer to a more complicated Cu(I) complex formation of CPGC. The observed 
difference emphasizes the importance of a well-defined, preorganized structure in the control 
of Cu(I) complex speciation. Furthermore, the apparent stability constant calculated for a 
theoretical CuP mononuclear complexes is one order of magnitude larger for CDPPC 
(logβ11pH7.4 = 17.5) than for CPGC (logβ11pH7.4 = 16.4). 
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The Zn(II) complexes of CDPPC and CPGC were demonstrated to be mononuclear 
ZnP or ZnP2 species. The apparent stability constants at physiological pH calculated for the 
ZnP complexes are in a magnitude of 106, and the selectivity in favor of Cu(I) with respect 
to Zn(II) is therefore extremely large. 
The Cu(I) complexation by CDPPC is strikingly different compared to what was 
previously observed with Hg(II). This supports that the use of Hg(II) as a probe of Cu(I) 
must be handled with extreme care. 
Since CDPPC forms a single Cu4P3 cluster with high stability and displays large 
selectivity for Cu(I) with respect to the ubiquitous Zn(II), it is an interesting simple peptide 
candidate to be targeted to the liver cells for the localized treatment of Cu overload in 
Wilson’s disease.  
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Összefoglalás 
A réz, mint létfontosságú nyomelem számos biológiai folyamatban vesz részt. Ilyen 
a légzés, a vas-háztartás, az oxidatív stressz elleni védelem vagy a pigment képz dés. 
Azonban ha a réz feleslegbe kerül,  maga is képes oxidatív károk okozására. Ezért sejten 
belüli koncentrációja szigorú szabályozás alatt áll. A Menkes és a Wilson betegségek 
genetikai elváltozások, melyek a szervezet réz-háztartásának felborulásához vezetnek és 
rézhiány ill., -felhalmozódás alakul ki. A Wilson betegség kelát-terápiával kezelhet , 
azonban a jelenleg alkalmazott gyógyszerek számos súlyos mellékhatást váltanak ki. 
Pascale Delangle kutatócsoportjának célja olyan új peptid vagy tripodális 
ligandumok kifejlesztése, melyek egyrészt nagy affinitást mutatnak a sejten belüli Cu(I) 
ionok iránt, másrészt célzottan a májsejtekbe képesek felszívódni, ezáltal csökkentve a 
mellékhatások kockázatát. 
Doktori munkám céljaként új peptid típusú, cisztein tartalmú ligandumok tervezését, 
valamint el állítását és Cu(I) ionokkal való kölcsönhatásának vizsgálatát tűztük ki célul, 
annak érdekében, hogy kiderüljön, a megtervezett és vizsgált vegyületek megfelel  
kelátorok lennének-e a Wilson betegség kezelésére. Egyes esetekben a peptidek Hg(II) és 
Zn(II) ionokkal való kölcsönhatását is tanulmányoztuk, mert a Hg(II) hasonló koordinációs 
kémiai tulajdonságokkal rendelkezik, mint a Cu(I) és emiatt gyakorta használják az 
oxidációra érzékeny Cu(I) helyett próbaionként, illetve a Zn(II) ion a szervezetben nagy 
mennyiségben fordul el  és így a Cu(I) potenciális vetélytársa lehet.  
A peptideket három különböz  stratégia alapján terveztük meg. Az els  csoport 
ligandumaiban a bakteriális rézháztartás-szabályozó CueR fehérje nagyfokú érzékenységét 
és szelektivitását igyekeztünk kihasználni. Ennek érdekében a CueR fehérjének a két 
ciszteint tartalmazó fémköt  szakaszát modellez  peptideket állítottunk el . A következ  
megközelítésben három ciszteint tartalmazó lineáris és ciklikus peptidek segítségével 
próbáltuk egyesíteni a Delangle csoportban korábban tanulmányozott ligandumok kedvez  
tulajdonságait, azaz a tripodális ligandumok nagy Cu(I) affinitását, illetve a peptid kelátorok 
azon tulajdonságát, hogy glikokonjugátumaikat a májsejtek nagyobb hatékonysággal 
képesek felvenni. Végül, a peptid szerkezetének nagyfokú preorganizációjából fakadó 
el nyöket terveztük kihasználni egy rövid, merev tetrapeptid segítségével, melyben két 
ciszteint egy turn motívum köt össze. Összehasonlíthatóság érdekében egy kevésbé merev 
vázú peptiddel végeztünk vizsgálatokat (CPGC). 
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A terminálisan védett lineáris peptideket szilárd fázisú peptidszintézissel állítottuk 
el  az Fmoc stratégiát követve. A ciklikus peptidek el állítása során el ször hasonló módon 
lináris prekurzorokat szintetizáltunk, melyeket a gyantáról való hasítás után híg oldatban, 
standard kapcsolószerek jelenlétében ciklizáltunk. A nyers termékeket fordított fázisú 
HPLC-vel tisztítottuk, majd tisztaságukat analitikai HPLC-vel és ESI-MS segítségével 
ellen riztük. 
Mivel mind a cisztein tiolcsoportjai, mind a Cu(I) ion oxidációra érzékeny, a minták 
el készítése és további kezelése inert atmoszférában, egy gloveboxban történt. A kísérletek 
többségét pufferelt közegben, 7,4-es pH-n hajtottuk végre. Néhány esetben pH függ  UV 
spektrumsorozatot is felvettünk állandó fémion:peptid arány mellett. A peptidek 
fémionokkal való kölcsönhatását UV-látható, CD és NMR spektroszkópiával, valamint ESI-
MS segítségével vizsgáltuk. A peptid-fémion komplexek stabilitását minden esetben az adott 
fémiont hatékonyan köt , jól ismert ligandummal végrehajtott kiszorításos reakcióval 
határoztuk meg. 
A CueR három modell peptidje, az EC, VC és HS nagyon hasonlóan viselkednek 
Cu(I) ionokkal történ  kölcsönhatásuk során. Ligandum felesleg jelenlétében egymagvú 
komplexek képz dnek, melyek átalakulnak többmagvú részecskékké, ha a fémion kerül 
feleslegbe. Az UV és CD spektrumokon a Cu(I)-ligandum arány növelésével párhuzamosan 
megjelen  tiolát-Cu(I) töltésátviteli sávok intenzitásának alakulása arra utal, hogy 7,4-es pH-
n a Cu(I) a két cisztein oldalláncán keresztül koordinálódik a peptidekhez. A HS esetében 
1H NMR vizsgálatokkal igazoltuk, hogy a hisztidin oldallánca is részt vesz a fémion 
megkötésében. A pH változtatásával felvett UV spektrumok azt mutatják, hogy a komplexek 
pH = 7 felett teljes mértékben kialakulnak, valamint, hogy a pH csökkenésével a cisztein 
tiolátok két lépésben dekoordinálódnak a fémiontól. Az ezen folyamatokra meghatározott 
pKs értékek jelent sen kisebbek a fiziológiás pH-nál, ami arra utal, hogy a pH indukálta tiol-
disszociációs folyamatok feltehet leg nem játszanak szerepet a CueR működése során. 
Az egymagvú komplexek BCA ligandummal való kiszorítási reakció segítségével 
meghatározott látszólagos stabilitása pH = 7,4-en meglehet sen nagy (logβ11pH7,4 ~ 16) és 
azonos nagyságrendű a CxxC vagy CxxxxC motívumot tartalmazó peptidek Cu(I)-
affinitásával. Ez arra utal, hogy a ciszteinek szekvencián belüli távolsága nem befolyásolja 
számottev en a peptidek Cu(I)-köt  hatékonyságát és a komplexek stabilitását els sorban a 
két Cu(I)-tiolát kötés er ssége határozza meg. Korábbi stabilitási eredményekkel való 
összehasonlítás alapján a peptidek jelent s szelektivitást mutatnak a Cu(I) ionok irányába a 
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Zn(II) ionokkal szemben, azonban a CuP komplexek stabilitása hasonló, mint a megfelel  
Ag(I) komplexeké. Habár a modell peptidek affinitása ő-6 nagyságrenddel elmarad a natív 
CueR fehérjéhez képest, ligandum felesleg jelenlétében a fehérjével megegyez  módon csak 
egyetlen fémiont kötnek meg. Ez, valamint a nagy Cu(I) affinitás, ill. a Zn(II) ionokkal 
szemben mutatott szelektivitás együttesen a Cu(I)-kelátorként való alkalmazás 
szempontjából kedvez  tulajdonságok. 
A három ciszteint tartalmazó ciklikus P3C, 1C, 2C és 3C peptidekben, valamint lineáris 
megfelel ikben, 1L-ben és 2L-ben, a cisztein aminosavak a metallotioneinekben is 
megtalálható CxCxxC és CxCxC motívumok szerint helyezkednek el. A peptidek ezen 
sorozatával azt is tanulmányoztuk, hogy a szekvenciát és a ligandum szerkezetet érint  
kisebb változtatások miként befolyásolják a fémion megkötését. 
Mind a hat peptid Cu(I) ionokkal való reakciója meglehet sen összetett rendszer 
kialakulásához vezetett. Ennek els  el jele az abszorbancia lassú stabilizálódása volt az UV 
spektroszkópiás vizsgálatok során, mikor a peptideket Cu(I)-oldattal titrálva az LMCT sávok 
intenzitása csak ~2 óra elteltével állandósult. Ezért további méréseinkhez egyedi mintákat 
alkalmaztunk. Az abszorbancia lineáris változása látszólag egyszerű folyamatra utal, 
melynek végpontja 2 ekvivalens Cu(I) hozzáadásakor figyelhet  meg. Ennek alapján a 
(Cu2P)n általános összetétellel egyszerűen leírható részecske képz dése feltételezhet . Ezzel 
szemben a CD- és ESI-MS spektrumok különböz  többmagvú részecskék bonyolult 
keverékének képz dését támasztja alá. A vizsgált peptidek szerkezete tehát túlságosan 
flexibilisnek bizonyult ahhoz, hogy egy jól definiált szerkezetbe kényszerítse a Cu(I) iont, 
amelynek következménye számos, els sorban többmagvú részecske együttes jelenléte a 
rendszerekben. 
Mivel a képz d  komplexek összetétele nem meghatározott, csak a peptidek átlagos 
Cu(I)-köt  affinitását tudtuk meghatározni. Ehhez a BCS ligandummal elvégzett 
kiszorításos reakció UV spektrumainak értékelésekor egy 1:1 összetételű, CuP általános 
képlettel leírható komplex képz dését vettük figyelembe. Minden peptid Cu(I)-affinitása 
jelent s és nagyságrendileg megegyezik a dajka fehérjékre jellemz  Cu(I)-köt  képességgel. 
A hasonló logβ11pH7,4 ~ 18 értékek arra utalnak, hogy a szerkezeti különbségek csak csekély 
mértékben befolyásolják a peptidek Cu(I)-affinitását. 
Annak felderítése érdekében, hogy a komplexképz dési folyamatok összetettsége a 
peptid szerkezetéb l adódik vagy az kifejezetten a Cu(I) ionokra jellemz , a peptidek 
kölcsönhatását egy másik szoft fémionnal, a Hg(II)-vel is megvizsgáltuk. Az els  
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szembetűn  különbség a Hg(II) komplexek jóval gyorsabb kialakulása. Ligandum felesleg 
jelenlétében HgP összetételű komplexek képz dnek. A tiolát-Hg(II) töltésátviteli sávok 
pozíciója λ = 280 és 240 nm-nél egyértelműen mutatja, hogy 7,4-es pH-n a peptidek 
mindhárom tiolát-csoportja részt vesz a fémion megkötésében. Hg(II) felesleget alkalmazva 
az egymagvú komplexek többmagvú részecskékké alakulnak át, melyekben a Hg(II) a 
kedvez bb HgS2 módon koordinálódik. Az UV és ESI-MS mérések eredményei 1,5 
ekvivalens Hg(II) hozzáadásáig a Hg2P3 összetételű komplex képz dését valószínűsítik, 
majd a Hg(II) felesleg további növelésével összetettebb részecskék alakulnak ki. 
A pH függvényében felvett UV spektrumok változása HgS2 és HgS3 koordinációs 
módú komplexek pH-függ  egyensúlyára utal, ahol a harmadik tiol-csoport 
deprotonálódására az egyes Hg(II)-peptid rendszerekben pKs = 4,3-5,1 értékeket határoztunk 
meg. Mivel ezek az értékek viszonylag közel esnek egymáshoz, a szerkezeti különbségek 
csak kis mértékben befolyásolják a HgS3 részecske stabilitását. A pKs értékek sorrendje 
alapján megállapítható, hogy a P3C peptid CxCxxC szekvenciája a HgS3 geometria 
kialakulásának szempontjából kedvez bb, mint a többi ligandum CxCxC motívuma, 
csakúgy, mint a 2C és 3C peptidekben a köt hely az 1C ligandumhoz képest nagyobb 
távolsága a PG motívumtól, illetve a ciklikus szerkezet a lineárishoz képest. A meghatározott 
pKs értékek mindegyike jelent sen kisebb, mint a háromszálú, ún. „coiled-coil” peptidek 
Hg(II)-komplexeire publikált deprotonálódási állandók, melynek valószínű oka a tiol-
csoportok eltér  oldószer-hozzáférhet sége a különböz  struktúrákban. 
A HgP komplexek látszólagos stabilitását pH = 2,0-n határoztuk meg I− ionokkal 
való kiszorítás segítségével. A hasonló stabilitási értékek azt mutatják, hogy a donor 
csoportok pozíciója és irányítottsága csekély mértékben befolyásolja a peptidek Hg(II)-köt  
képességét, és a fémion nagy tiofilicitása elegend  hajtóer  a pH = 2,0-n megfigyelt HgS2 
szerkezet kialakulásához. A 7,Ő-es pH-ra átszámolt látszólagos stabilitási állandók 20 
nagyságrenddel nagyobbak, mint a Cu(I) komplexek azonos körülmények között 
meghatározott stabilitása, ami a Hg(II) ionok jelent sebb tiofil karakterének tulajdonítható. 
A HgP komplexek stabilitási állandói hasonlóak, mint a jól ismert nehézfém-kelátor BAL 
Hg(II) komplexéé, melyben kiemelten stabilis, öttagú kelátgyűrű képz dik a fémion 
koordinálódása során. Ugyanakkor peptidjeink HgS3 típusú komplexeinek stabilitása 
nagyobb annál, mint amit a merev szerkezetű CDPPC peptid Hg(II) komplexére 
meghatároztak, mely a koordinálódó donorcsoportok növekv  számának logikus 
következménye. A nagy stabilitási állandók és az alacsony pKs értékek bizonyítják, hogy 
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ezek a három ciszteint tartalmazó peptidek kiválóan alkalmasak a Hg(II) ionok tritiolát 
koordinációs környezetben való megkötésére. 
A peptidek a két szoft karakterű fémionnal szembeni viselkedésében megmutatkozó 
markáns különbségek azt tükrözik, hogy a Hg(II) nem minden esetben alkalmazható modell 
ionként a Cu(I) tiol-tartalmú peptidekkel vagy fehérjékkel fiziológiás körülmények között 
való kölcsönhatásának tanulmányozására. 
A peptidszerkezet preorganizáltságának fémion megkötésére gyakorolt hatását két 
olyan rövid tetrapeptid segítségével vizsgáltuk, melyekben két ciszteint egy β turn 
kialakítására képes motívum köt össze. Ezek a motívumok a CDPPC peptidben alkalmazott 
DPro-Pro, illetve a CPGC Pro-Gly egysége voltak. A cisztein egységek amid nitrogénjeinek 
1H NMR jeleinek h mérsékletfüggését vizsgálva meggy z dtünk arról, hogy a DPro-Pro 
motívum merevebb peptidszerkezetet képes biztosítani. UV, CD és NMR spektroszkópiás 
titrálások alapján megállapítottuk, hogy a CDPPC csupán egyfajta Cu(I) komplexet képez 
1,33 ekvivalens fémion hozzáadásáig. ESI-MS és DOSY NMR mérések bizonyították, hogy 
ez a részecske egy Cu4P3 összetételű klaszter Cu4S6 maggal, melyben egy fémiont három 
tiolátcsoport vesz körbe. Ez az egyszerű rövid peptid figyelemre méltó módon utánozza 
számos Cu(I)-köt  fehérje, pl. a Ctr1 vagy Cox17 réz-tiolát klaszterképz  képességét. Ezzel 
ellentétben, a CPGC peptiddel elvégzett kísérletek jóval összetettebb, komplikáltabb 
komplexképz dési folyamatra utalnak. A CDPPC Cu(I) komplexének stabilitása (logβ11pH7,4 
= 17,5) körülbelül egy nagyságrenddel nagyobb, mint a PG motívumot tartalmazó rokon 
ligandumé (logβ11pH7,4 = 16,4). A két peptid viselkedésének összevetése alapján elmondható, 
hogy a jól meghatározott, preorganizált szerkezet kulcsfontosságú a Cu(I) komplex 
speciációjának szabályozásában. 
A CDPPC és CPGC peptidek Zn(II) ionnal való kölcsönhatása során ZnP és ZnP2 
komplexek képz dését figyeltük meg. Fiziológiás pH-n a ZnP komplexek látszólagos 
stabilitási állandói a 106-os nagyságrendbe esnek, ami a peptidek kimagasló Cu(I)-
szelektivitását mutatja Zn(II) ionokkal szemben. 
CDPPC Cu(I) komplexképz  sajátságai jelent sen különböznek a korábban vizsgált 
Hg(II) komplexekét l, ami újabb bizonyíték arra vonatkozóan, hogy a Hg(II), mint Cu(I)-
próbaion, csak nagy körültekintés mellett alkalmazható. 
A CDPPC peptid jól definiált Cu(I) koordinációja és a Zn(II) ionnal szemben mutatott 
jelent s szelektivitása alapján ígéretes vegyület a májsejteket célzó funkcionalizálásra, és 
ennek révén alkalmas lehet a Wilson betegség során felhalmozódó Cu(I) célzott 
eltávolítására is.  
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Résumé 
Le cuivre est un micronutriment essentiel qui participe à de nombreux processus 
biologiques, comme par exemple la respiration, l’homéostasie du fer, la lutte contre le stress 
oxydant ou la production de pigments. Cependant, le cuivre libre est toxique pour 
l’organisme parce qu’il catalyse une réaction de type Fenton formant des espèces réactives 
de l’oxygène. Par conséquent la concentration en cuivre est finement régulée dans tous les 
organismes vivants. Les maladies de Menkes et de Wilson sont dues à des dérèglements de 
l’homéostasie du cuivre qui se manifestent respectivement par une déficience ou une 
accumulation de cuivre dans l’organisme. La maladie de Wilson est traitée avec des 
chélateurs du cuivre, qui provoquent des effets secondaires importants chez certains patients. 
C’est pourquoi, l’équipe CIBEST propose de nouveaux chélateurs sélectifs du cuivre(I) et 
ciblés vers le foie qui est le premier organe touché. 
Mon projet de doctorat consiste en l’élaboration de trois familles de peptides qui 
contiennent des acides aminés cystéines et en l’étude de leurs complexes de Cu(I) pour 
déterminer s’ils sont des candidats adaptés pour le traitement de la maladie de Wilson. 
L'interaction de certains peptides avec les ions Hg(II) ou Zn(II) a également été étudiée. En 
effet, le Hg(II) est un cation métallique possédant des propriétés similaires au Cu(I) et donc 
souvent utilisé pour modéliser le Cu(I) qui est sensible à l'oxygène et se dismute dans l’eau. 
Le Zn(II) est quant à lui omniprésent dans les cellules et un compétiteur intracellulaire 
potentiel du Cu(). 
Les séquences des peptides ont été choisies selon trois stratégies différentes. Dans la 
première, des séquences inspirées de la boucle de liaison du cuivre de la protéine bactérienne 
CueR (copper efflux regulator), contenant deux cystéines, ont été étudiées afin de bénéficier 
de la sélectivité et de la sensibilité de ce régulateur. Dans une deuxième approche, des 
peptides contenant trois cystéines dans les motifs CxCxxC et CxCxC ont été étudiés pour 
combiner les avantage des peptides (bonne internalisation dans les cellules hépatiques quand 
ils sont judicieusement fonctionnalisés) et des tripodes (très forte affinité pour le Cu(I)) de 
l’équipe CIBEST. Finalement, la pré-organisation a été exploitée dans un tétrapeptide rigide 
où les deux cysteines sont liées dans un coude β préformé. 
La synthèse des peptides linéaires, protégés en N-ter et C-ter, a été réalisée par 
synthèse peptidique en phase solide (SPPS) en utilisant la stratégie « Fmoc ». Pour obtenir 
les peptides cycliques, les précurseurs linéaires protégés sur leurs chaînes latérales et avec 
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des extrémités N-ter et C-ter libres ont été synthétisés par SPPS. Après avoir décroché le 
peptide de la résine, la cyclisation a été réalisée dans une solution diluée. Les peptides 
obtenus ont été purifiés par HPLC et leur pureté a été vérifiée par HPLC analytique et ESI-
MS. 
Pour obtenir la stabilité, la composition et le mode de liaison des complexes, des 
mesures par spectroscopie UV-visible, dichroïsme circulaire, RMN et ESI-MS ont été 
réalisées. Les mesures ont été préférentiellement effectuées en boîte à gants car les ligands 
et l’ion Cu(I) sont sensibles à l’oxydation. La plupart des expériences ont été réalisées à pH 
= 7.4 en milieu tamponné. Dans certains cas, l’effet du pH a été analysé pour des rapports 
métal:ligand constants. Afin de déterminer la stabilité des complexes, des compétiteurs dont 
l’affinité pour les ions métalliques est connue, ont été utilisés. 
Les trois peptides modèles du régulateur CueR, EC, VC et HS, étudiés lors de ma 
thèse, se comportent de la même façon avec le Cu(I). Ils forment des complexes 1:1 en excès 
de ligand, qui se transforment en espèce polynucléaire en excès de Cu(I). L’analyse des 
bandes LMCT sur les spectres UV et CD montre que le Cu(I) est lié par les deux groupes 
thiolates des cystéines. Le spectre de RMN du proton indique également la coordination de 
l’histidine du peptide HS. L’analyse des spectres UV en fonction du pH révèle que la 
formation des complexes est complète au-dessus de pH = 7.0 et que la diminution de pH 
provoque la décoordination des cystéines en deux étapes en menant à la perte totale de 
l’absorbance des bandes LMCT. Les pKa obtenus pour ces deux processus sont 
significativement en dessous du pH physiologique, ce qui indique qu'ils ne sont 
probablement pas pertinents pour la séquestration biologique du Cu (I). 
Les stabilités des complexes mononucléaire à pH = 7.Ő, déterminées en présence du 
compétiteur BCA, sont élevées (logβ11pH7.4 ~ 16) et similaires à la stabilité des complexes 
avec des peptides incorporant le motif CxxC ou le CxxxxC. Ce résultat montre que la 
distance entre les résidus Cys dans le peptide affecte peu l'affinité pour le Cu(I). Par 
conséquent, la force motrice de la coordination du cation mou Cu(I) est principalement due 
à la formation des deux liaisons fortes avec les donneurs thiolates mous. La comparaison des 
constantes de stabilité avec les résultats précédents montre que les peptides sont fortement 
sélectifs pour le Cu(I) par rapport au Zn(II), mais ont une affinité similaire pour l’Ag(I). Les 
affinités pour le Cu(I) de ces peptides modèles sont plus faibles, de ő à 6 ordres de grandeur, 
que celle de la protéine CueR native. Néanmoins, ces peptides miment la capacité de la 
protéine à accueillir exclusivement un ion Cu(I) dans des conditions d'excès de ligand et une 
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forte affinité et sélectivité par rapport au Zn(II). Ces caractéristiques sont avantageuses dans 
la perspective du développement de nouveaux chélateurs du Cu(I). 
Dans les peptides contenant trois cystéines, P3C, 1C, 2C, 3C, 1L et 2L, les résidus Cys 
sont placés dans les motifs CxCxxC ou CxCxC identifiés dans les métallothionéines. Cette 
série de peptides a permis d’évaluer les effets des modifications structurales sur la 
coordination des ions métalliques Hg(II) et Cu(I). 
La complexation du Cu(I) s’est avérée compliquée avec les six peptides. Une 
première difficulté a été les longs temps d’équilibration (supérieurs à 2 heures) lors de la 
formation des complexes. Par conséquent, les échantillons de stœchiométries données ont 
été préparés individuellement. Malgré l’évolution simple des spectre UV, qui indique la 
formation des complexes avec la stœchiométrie (Cu2P)n, les spectres CD et ESI-MS 
démontrent la présence de plusieurs espèces polymétalliques. Ces peptides s’avèrent donc 
trop flexibles pour contrôler la spéciation des complexes du Cu(I). Une affinité moyenne de 
ces peptides pour le Cu(I) a été déterminée à pH = 7.Ő. Le résultat des compétitions avec le 
ligand BCS a été évalué en considérant la formation d’un seul complexe 1:1 mononucléaire. 
Tous les peptides ont une forte affinité pour le Cu(I), typique des protéines chaperonnes du 
Cu(I). Les valeurs des constantes de stabilité (logβ11pH7.4 ~ 18) sont similaires sur la série, ce 
qui indique que la structure des peptides influence peu la stabilité des complexes de Cu(I) 
formés. 
Afin de comprendre si le comportement complexe observé avec le Cu(I) provenait 
de la séquence peptidique ou des propriétés de coordination du Cu(I), l’interaction avec le 
Hg(II), un ion métallique mou aux propriétés similaires à celles du Cu(I), a également été 
étudiée. Des complexes mononucléaires de Hg(II) se forment quand le ligand est en excès. 
Leur formation est significativement plus rapide qu’avec le Cu(I). La position des bandes 
LMCT pour λ = 280 et 2Ő0 nm démontre que le Hg(II) est coordonné par les trois cystéines 
à pH = 7.Ő. En excès de Hg(II), les complexes mononucléaires se transforment en espèces 
polymétalliques pour adopter une coordination de type HgS2, très favorable. Les dosages 
UV et les expériences de spectrométrie de masse confirment la formation de complexes 
Hg2P3 en excès de Hg(II). 
L’équilibre de transformation HgS2 ⇌ HgS3 est mis en évidence par l’évolution des 
spectres UV avec le pH, avec des pKa = 4.3-5.1, qui caractérisent la déprotonation d’un 
troisième thiol. Ces valeurs sont relativement proches pour les six peptides, ce qui indique 
que la structure des peptides affecte peu la stabilité des complexes de Hg(II). Cependant, la 
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tendance observée révèle que le motif CxCxxC dans le peptide cyclique P3C est plus 
favorable que le motif CxCxC, et que les structures cycliques sont plus favorables que les 
linéaires. Il est intéressant de noter que ces pKa ont des valeurs significativement en dessous 
de celles obtenues avec les « three-stranded coiled coils » (pKa = 7-9), probablement grâce 
à une hydratation plus forte des groupes thiols accessibles à l’eau dans nos peptides de 
structures exposées. 
Les constantes apparentes de stabilité des complexes HgP ont été déterminées à pH 
= 2.0 par compétition avec I−. Les six peptides ont des affinités similaires pour le Hg(II), ce 
qui montre que la pré-orientation des groupes donneurs n’a qu’une influence modeste sur les 
stabilités et que la forte affinité du Hg(II) pour les groupes thiolates gouverne la formation 
de la coordination HgS2 préférée. Les constantes de stabilité apparentes estimées à pH = 7.Ő 
montrent une affinité pour le Hg(II) plus forte de 20 ordres de grandeurs que pour le Cu(I) 
en raison du caractère plus mou du Hg(II). Les stabilités des complexes HgP sont similaires 
à celles mesurées avec des chélateurs classiques des métaux lourds comme le BAL, qui 
forme un cycle chélate à cinq chaînons très stable par la coordination de deux groupes 
thiolates. Par ailleurs, nos peptides à 3 cystéines ont une affinité pour le Hg(II) plus grande 
que le peptide rigide CDPPC portant 2 cystéines, car le nombre de groupes thiolates 
coordonnés à pH 7.Ő est plus élevé. La stabilité élevée et les valeurs faibles des pKa indiquent 
que ces peptides sont bien adaptés pour une coordination efficace du Hg(II) par trois groupes 
thiolates. 
La différence dans la coordination des peptides vis-à-vis des deux ions mous Hg(II) 
et Cu(I) démontre que l'utilisation du Hg(II) comme ion modèle pour la coordination du 
Cu(I) avec des peptides ou des protéines riches en soufre dans des conditions physiologiques 
n’est pas toujours appropriée. 
Dans une dernière partie, l’effet de la pré-organisation sur la coordination d’ion 
métallique a été étudié avec deux tétrapeptides dans lesquels les deux cystéines sont liés dans 
un motif de type coude β : DPro-Pro (CDPPC) et Pro-Gly (CPGC). La structure plus rigide 
de CDPPC a été confirmée par des études en température par RMN du proton, qui montrent 
l’existence d’une liaison hydrogène intramoléculaire entre groupe C=O de la Cys1 et le 
groupe NH de la CysŐ. Les dosages UV, CD et RMN révèlent que CDPPC forme un seul 
complexe de Cu(I) jusqu’à l’addition de 1.33 équivalents de Cu(I). La RMN DOSY et l’ESI-
MS prouvent que c’est un cluster de type Cu4P3 avec un cœur Cu4S6 dans lequel les ions 
Cu(I) sont liés dans la coordination favorable trithiolate. Il est intéressant de noter que ce 
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peptide simple est capable d’imiter la formation des clusters Cu(I)-thiolates identifiés dans 
de nombreuses protéines impliquées dans l’homéostasie du cuivre, comme Cox17 ou Ctr1. 
Au contraire, les données expérimentales avec le tétrapeptide plus flexible CPGC montrent 
la formation d’un mélange de complexes polymétalliques de Cu(I). Les différences 
observées démontrent l’importance de la structure du peptide et de sa pré-organisation dans 
le contrôle de la spéciation des complexes de Cu(I). De plus, la constante apparente de 
stabilité calculée pour un complexe 1:1 CuP est plus grande d’un ordre de grandeur pour le 
peptide rigide CDPPC (logβ11pH7.4 = 17.5) que pour le peptide plus flexible CPGC (logβ11pH7.4 
= 16.4). 
Les complexes de Zn(II) formés avec CDPPC et CPGC sont des espèces 
mononucléaires ZnP ou ZnP2. Les constantes apparentes de stabilité calculées pour le 
complexe ZnP sont de l’ordre de 106 et la sélectivité pour le Cu(I) par rapport au Zn(II) est 
donc extrêmement élevée. 
A nouveau, les complexes du Cu(I) avec CDPPC sont très différents de ceux observés 
précédemment dans la littérature avec le Hg(II). Cela confirme que l'utilisation du Hg(II) 
comme modèle du Cu(I) doit être traitée prudemment. 
Le peptide CDPPC forme uniquement le cluster Cu4P3 avec une grande stabilité et 
une bonne sélectivité Cu(I)/Zn(II) ; il est donc intéressant pour mettre au point un chélateur 
intracellulaire du Cu(I), et sa fonctionnalisation afin de pouvoir cibler les cellules hépatiques 
pour le traitement de maladie Wilson sera donc pertinente dans le futur. 
  
124 
List of publications 
Identification number in the Hungarian Collection of Scientific Publications (MTMT): 
10054976 
Publications related to the dissertation 
1. E. Mesterházy, B. Boff, C. Lebrun, P. Delangle and A. Jancsó, Oligopeptide 
models of the metal binding loop of the bacterial copper efflux regulator protein 
CueR as potential Cu(I) chelators, Inorg. Chim. Acta, 2018, 472, 192-198. 
IF = 2.264 
2. E. Mesterházy, C. Lebrun, A. Jancsó and P. Delangle, A Constrained Tetrapeptide 
as a Model of Cu(I) Binding Sites Involving Cu4S6 Clusters in Proteins, Inorg. 
Chem., 2018, 57, 5723-5731. 
IF = 4.700 
3. E. Mesterházy, C. Lebrun, S. Crouzy, A. Jancsó and P. Delangle, Short 
oligopeptides with three cysteine residues as models of sulphur-rich Cu(I)- and 
Hg(II)-binding sites in proteins, Metallomics, 2018, DOI: 10.1039/C8MT00113H. 
published online 
IF = 4.069 
ΣIF = 11.033 
Further publication 
1. A. Jancsó, B. Gyurcsik, E. Mesterházy and R. Berkecz, Competition of zinc(II) 
with cadmium(II) or mercury(II) in binding to a 12-mer peptide, J. Inorg. 
Biochem., 2013, 126, 96-103. 
IF = 3.274 
Oral presentations and posters 
1. Mesterházy, E., Jancsó, A., Lebrun, C., Tömösi, F., Delangle, P., A Wilson 
betegség kezelésére potenciálisan alkalmas Cu(I) kelátorok 
ő0. Komplexkémiai Kollokvium, Balatonvilágos, 2016. 
2. Mesterházy, E., Jancsó, A., Lebrun, C., Tömösi, F., Delangle, P., New peptidic 
Cu(I) chelators as potential candidates for the treatment of Wilson’s disease 
13th European Biological Inorganic Chemistry Conference, Budapest, 2016. 
3. Mesterházy, E., Jancsó, A., Lebrun, C., Delangle, P., Interaction of copper(I) with 
12-mer peptides mimicking the metal binding domain of CueR, a copper-efflux 
regulator 
Journées de Chimie de Coordination de la SCF, Grenoble, 2017 
4. Mesterházy, E., Lebrun, C., Jancsó, A., Delangle, P., An Efficient Peptidic 
Copper(I) Chelator with Two Cysteines Linked by a Strong Turn 
14th International Symposium on Applied Bioinorganic Chemistry , Toulouse, 2017 
5. Mesterházy, E., Lebrun, C., Jancsó, A., Delangle, P., Cu(I)ionok hatékony 
megkötésére alkalmas β-turn motívumot és két ciszteint tartalmazó tetrapeptid 
ő2. Komplexkémiai Kollokvium, Balatonvilágos, 2018. 
125 
6. Mesterházy, E., Lebrun, C., Crouzy, S., Jancsó, A., Delangle, P., Metalloproteinek 
cisztein-gazdag Cu(I)- és Hg(II)-köt helyeit utánzó modellpeptidek 
ő2. Komplexkémiai Kollokvium, Balatonvilágos, 2018. 
7. Mesterházy, E., Lebrun, C., Crouzy, S., Jancsó, A., Delangle, P., Oligopeptide 
models of cysteine-rich Cu(I)- and Hg(II)-binding metal sites of metalloproteins 
14th European Biological Inorganic Chemistry Conference, Birmingham, 2018. 
8. Mesterházy, E., Jancsó, A., Gyurcsik, B., Berkecz, R., Zinc(II) interaction of a 12-
mer peptide and competition of group 12 ions in binding to the ligand 
REGIONAL CONFERENCE “Heavy metal as contaminants of the environments”. 
Timisoara, Romania, 2013 
9. Balogh, R.K., Mesterházy. E., Gyurcsik, B., Jancsó, A., Christensen, H. E. M., 
Asaka, M.N., Kato, K., Nagata, K., Réz(I)ionok szelektív kimutatása a CueR 
fémszabályzó fehérje segítségével 
XXXVIII. KÉMIAI EL ADÓI NAPOK, Szeged, 201ő. 
10. Balogh, R.K., Mesterházy. E., Kato, K., Nagata, K Jancsó, A., Gyurcsik, B. 
Detection of toxic metal ions by the CueR metalloregulator 
14th European Biological Inorganic Chemistry Conference, Birmingham, 2018. 
  
126 
Acknowledgement 
I wish to express my deepest gratitude to my supervisors, Dr. Pascale Delangle and 
Dr. Attila Jancsó for assisting my scientific development and their valuable help during the 
years of the PhD and for that they did not give up in the labyrinth of the administration of 
the co-tutelle. 
Many thanks to the Queen of MS, Colette Lebrun for performing the ESI-MS 
experiments and for her help in the peptide synthesis and HPLC experiments. 
I would like to thank Pierre-Alan Bayle his guide with NMR experiments. 
I say thank you to Dr. Béla Gyurcsik for giving me the opportunity for the little trips 
to the field of molecular biology and to Japan. 
I owe thanks to my family and to those wonderful people I met in the “PhD room” 
and in the SyMMES group for their support in the past years. 
I kindly acknowledge the financial support providing by the French Government and 
Campus France enabling the co-tutelle PhD program. 
